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ENHANCING HPV-VACCINE COMMUNICATION 
 
Abstract 
Background: Human Papillomavirus (HPV) is a common infection, where persistent disease may 
result in the development of malignancies.  Minority populations are at increased risk for 
developing these cancers. Current guidelines recommend all adolescents receive HPV-
vaccination.  Patient education plays a critical role in willingness to vaccinate, however despite 
the availability of print materials, successful HPV-vaccination rates continues to lag behind other 
adolescent immunizations. Language-congruent interventions in a variety of multimodal 
implementation strategies have demonstrated efficacy at increasing HPV-vaccination acceptance.  
Purpose: This project included an integrative review of literature examining educational 
strategies aimed at increasing HPV-vaccine acceptance followed by implementation of a toolkit 
and resource packet detailing concepts critical to unique needs of minority populations aimed at 
increasing vaccine acceptance.  Methods: A toolkit was developed utilizing agency guidelines. A 
resource packet containing multimedia educational tools was presented.  Efficacy of this project 
was assessed through questionnaires completed pre and post-intervention.  Results: Participants 
felt the toolkit and resource packet were helpful to their practice and positively influenced their 
ability to provide HPV-education to patients. Yet, one month following the intervention, 
respondents reported they utilized the information “moderately” or “not at all.” Conclusion: To 
further examine the efficacy of this toolkit, future distribution of the materials to a larger sample 
in a variety of settings, including school based health clinics, and to providers who are integral to 
delivery of HPV-vaccine information would be beneficial.   
 Keywords: HPV vaccine, HPV immunization, vaccine education, educational 
intervention, nursing education 
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Introduction 
Background 
 Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) 
in the United States and is often asymptomatic.  Untreated or persistent infection by certain 
strains of HPV may lead to malignancies, primarily cervical, oropharyngeal, penile, and anal 
cancers.  While HPV was initially deemed a virus with deleterious effects in women, we now 
know that men are also at significant risk for developing HPV related cancers as well.  HPV 
causes 17,000 cases of cancer in women and 9,000 cases in men each year (Burden of HPV 
Cancer, 2015). Despite this prevalence, HPV related cancers are essentially preventable.  Current 
guidelines recommend the two-dose HPV-vaccine series be administered to both adolescent boys 
and girls beginning at age 11 or 12.  This represents a recent change in recommendation which, 
until October 2016, consisted of a three-shot series. Nationwide four in ten adolescent girls and 
five in ten adolescent boys remain unvaccinated (HPV vaccine coverage, 2016).  Of the 
adolescents who begin HPV-vaccination, many do not complete the series, having received only 
a portion of the originally recommended three-shot series.  The national vaccination rate for 
females who have received at least one dose is only 63% and lower in males (50%) (HPV 
vaccine coverage, 2016).  Vaccination rates continue to hover well below the Healthy People 
2020 target of 80% (Healthy People, 2016). 
The incidence of HPV infection is associated with marked disparities, notably among 
minority groups resulting in increased healthcare costs, morbidity, and mortality.  Cervical 
cancer incidence is increased in African American women (8.9 per 1,000). Hispanics (9.4 per 
1,000), and American Indians and Alaska natives (7.7 per 1,000) compared to 7.5 per 1,000 
white women (SEER stat fact sheet, 2013).  Additionally, women in certain geographical 
ENHANCING HPV-VACCINE COMMUNICATION 
 
5 
locations display increased incidence and mortality from cervical cancer.  The highest incidence 
rates are noted in the Appalachian region, South Atlantic, lower Mississippi valley, and Texas-
Mexico border (Horner et al., 2011).  Individuals from low socioeconomic status are also 
disproportionately affected as they are less likely to have health screening tests, may present for 
healthcare less frequently, and are more likely to engage in behaviors such as risky sexual 
activity and smoking than those from higher socioeconomic classes.  Additionally, they may not 
speak English well, be unable to coordinate physician appointment times with their work 
schedules, or be unable to get transportation for health care (CDC, 2014). These barriers alone 
may decrease opportunities to vaccinate adolescents.  Adolescents and parents also self-report 
barriers to vaccination including the need for additional educational materials about HPV related 
diseases and HPV-vaccine information such as safety and effectiveness (Guerry et al, 2011; 
Francis et al 2013).  
Patient and family education is associated with increased willingness to vaccinate 
(Ylitalo et al, 2013; Rahman et al, 2015; Guerry et al, 2011).  However, despite availability of 
educational brochures and online information, vaccination rates continue to be low. Fu and 
colleagues (2014) conducted a systematic review of the effect of educational interventions on 
HPV-vaccination acceptance and identify no one type of educational intervention as more 
effective than another.  However, this review highlighted studies primarily evaluating well-
educated females with high-literacy levels and of higher socioeconomic status and included only 
one study in which a culturally-tailored intervention was examined.   
It remains uncertain whether specific educational modalities have a greater impact on 
high-risk populations than others.  Tailored educational interventions targeting the unique needs 
of high risk populations, such as language barriers and cultural differences, have not yet been 
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evaluated on a large scale.  Tailoring education to adolescents’ and parents’ specific needs may 
increase awareness, acceptance, and subsequent successful vaccine series completion.   
Education plays a successful role in increasing the acceptability of HPV-vaccination, yet 
HPV and related cancers continue to affect a greater proportion of certain populations.  
Examination of the literature through integrative review is warranted to decrease such disparity.  
Alternative educational methods may address the unmet needs of high-risk patients by increasing 
HPV-related knowledge and inclination towards successful vaccination.   
Problem, Purpose & Summary of Plan  
Problem. 
The risk of future human papillomavirus (HPV) related cancers remains high in 
individuals unvaccinated against HPV.  Minority group populations are at increased risk for 
developing HPV related cancers.  Rates of HPV-vaccination among American adolescents 
remain low despite national guidelines strongly recommending vaccination.  Primary care 
providers’ recommendation to vaccinate and family education about HPV and vaccine efficacy 
have a positive impact on a family’s decision to vaccinate.  
Purpose. 
This DNP project sought to evaluate through integrative review whether certain 
educational modalities were more effective for delivering HPV-vaccine information to at-risk 
populations, including minority groups. Based on these findings the DNP student provided a 
pediatric primary care practice with: 1) a toolkit aimed at enhancing provider/patient 
communication about HPV vaccination; and 2) a resource packet containing alternative 
educational modalities. Healthcare providers were thus equipped with knowledge, materials, and 
diverse educational strategies to improve their communication with patients about the HPV-
ENHANCING HPV-VACCINE COMMUNICATION 
 
7 
vaccine. 
Summary of plan. 
The DNP student completed the integrative review and determined the specific 
implementation practice site needs based on surveys completed by nursing staff at the project 
site.  The resource packet was then tailored to the identified needs of the practice before 
presentation of the toolkit and resource packet.  Efficacy of the toolkit and project were 
determined by analyzing post-intervention survey questionnaires.  
Review of the Literature  
The cornerstone of this DNP project was an integrative review of literature examining 
alternative educational modalities for at-risk patients for HPV.  Inclusion criteria: The review 
considered studies that included adolescent males and females age 9-18 who are, or will be, 
eligible for the HPV-vaccine, as well as the parents of these adolescents.  Types of intervention: 
This review considered studies that examined educational interventions differing from the 
standard education about HPV, diseases related to HPV, and the HPV-vaccine.  The 
interventions may occur in medical settings, as well as community settings, such as health 
centers, and community centers, and patient’s own homes.  Comparators for this review were 
standard care, which includes no tailored educational intervention.  Types of outcomes:  This 
review considered studies that included the following outcomes: actual HPV-vaccination rate, 
uptake, completion, as well as HPV-vaccine intention, attitudes, knowledge, and acceptance.  
Types of studies:  This review considered both experimental and epidemiological study designs 
including randomized controlled trials, non-randomized controlled trials, quasi-experimental 
studies, before and after studies, prospective and retrospective cohort studies, case control 
studies and analytical cross sectional studies for inclusion. In addition, descriptive 
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epidemiological study designs including case series, individual case reports and descriptive cross 
sectional studies were included. 
The search strategy aimed to find both published and unpublished studies. Only studies 
published in English between the years 2010 and 2016 were considered for inclusion in this 
review. The databases searched included: 
• MEDLINE, CINAHL, PsychINFO, PsychARTICLES, ScienceDirect, 
WileyOnlineLibrary, Virginia Henderson Library of Sigma Theta Tau 
• The search for unpublished studies included: 
Google Scholar, New York Academy of Medicine Grey Literature Report 
• keywords used: 
HPV vaccine; education; intervention; adolescent; uptake; acceptance 
Quantitative data was extracted from papers included in the review, and pooled and 
grouped according to category of the various educational modalities.  The data extracted 
included specific details about the interventions, populations, study methods and outcomes of 
significance to the review question and specific objectives.  Efficacy of the educational 
interventions was generalized for purposes of comparison for this review. 
The databases keyword search revealed a total of 183 articles.  Of these, thirty-nine were 
identified through analysis of abstracts as applicable to the purposes of this review.  Upon further 
review of each text, seventeen articles met criteria for the review portion of this project. Of the 
included studies, six were randomized controlled trials, eight were cross sectional studies, one 
was a case study, one was a prospective cohort study, and one was a quasi-experimental study.  
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These articles were systematically examined, and data was extracted and synthesized to reveal 
several themes as described in the following subsections. 
Language or literacy tailored education 
Eight of the examined articles included an English-language alternative as a component 
to the intervention.  Of these, the educational methods differed.  Three examined language-
specific pamphlets, two DVD videos, one tablet application, one radio segment, one Power Point 
presentation, and four studies included a language-tailored question and answer session with a 
healthcare provider as a component to the intervention.  Each of these language-specific 
interventions was associated with an increase in HPV-vaccine intention or acceptability. One 
cross sectional study examined use of tablets with language-specific educational multimedia 
followed by self-persuasion tasks consisting of open-ended vaccination related questions; an 
81% HPV-vaccination rate was noted after participation (Baldwin et al, 2016).  Foley and 
colleagues (2015) identified an increased willingness to vaccinate against HPV after non-English 
speaking participants were exposed to Spanish educational pamphlets, radio segments, and 
educational sessions at Hispanic community centers.  In addition, participants exposed to 
language specific brochures demonstrated an increase in HPV knowledge and vaccine intention 
(Obulaney et al, 2016).  Ability to understand the educational materials played a key role in 
decisions about HPV-vaccination.  Participants exposed to language-congruent DVDs tailored to 
specific knowledge gaps of Latino or Korean American parents attained increased knowledge 
about HPV, improved informed decision making, and decreased perceived decisional conflict 
compared to parents exposed to CDC vaccination fliers (Valdez et al.,2015).  While this was one 
of the few randomized controlled trials reviewed, this study did not examine actual vaccination 
uptake or acceptance, and was subject to self-selection bias. 
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The wording and appearance of educational literature may affect the readability of such 
documents for certain populations.  One study examined the use of a comic book among parents 
and adolescents as a means of providing HPV education. Parents attained increased knowledge 
and reported more positive attitudes towards HPV-vaccination after viewing the comic book.  
Adolescents enjoyed the comic book and reported it as an effective vehicle for learning about 
HPV (Katz et al., 2014).  This method of education may have been more acceptable for a 
population with lower literacy, or with an aversion to typical informational handouts.  
Brueggmann and colleagues (2016) exposed Spanish-speaking mothers to pamphlets outlining 
“10 easy to understand facts” about HPV. Those who reported comprehension of the information 
also demonstrated higher HPV-vaccine acceptability ratings.   
Technologies 
Technologies were important to the acceptability of the educational intervention in eleven 
of the examined studies.  Four articles examined use of DVD educational presentations, a tablet, 
a radio segment, Power Point presentations, an educational website, or a text/email intervention.  
Appalachian Kentucky women were 2.44 times more likely to complete the three-shot series 
after exposure to an informational DVD about HPV related disease than women exposed to 
standard of care in one randomized controlled trial (Vanderpool et al., 2013).  Spanish radio 
segments consisting of announcements focusing on cervical cancer awareness were a component 
of one intervention that was associated with parent’s greater willingness to have their children 
vaccinated (Foley et al, 2015).  The radio segments were combined with other educational 
strategies including HPV educational sessions held at community based centers; it remains 
unclear whether this effect was due to language specific radio segments or a combination of all 
educational methods.  
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PowerPoint presentations were associated with an increase in HPV awareness and 
relation to cervical cancer, as well as increased intention to vaccinate daughters (67% pre-
intervention compared to 86% post-intervention) (Li et al, 2015).  Parents had higher knowledge 
self-ratings following PowerPoint presentation in Appalachian North Carolina (Reiter et al, 
2011).  Spleen and colleagues (2012), completed a cross sectional study examining a 60-minute 
PowerPoint presentation and group discussion.  One month following the intervention, 100% of 
participants reported the intervention as helpful, and 44% had initiated vaccination.  
Richman and colleagues (2016) conducted a randomized controlled trial to examine the 
effect of a program consisting of seven text or email HPV educational messages combined with 
appointment reminders sent to participants.  There was no difference between the intervention 
group and the control group in vaccine uptake as reflected by actual dose completion score.  
However, knowledge scores were higher in the intervention group. 
An HPV infection and vaccination educational website (www.gohealthygirls.org) was 
developed and piloted with parents of adolescents.  The descriptive case report details findings 
that participants claimed the site was an appealing way to learn about HPV and vaccination 
(Starling et al, 2014).  Unfortunately, this study did not measure actual vaccine intent, but only 
the ease and appeal of the website. 
Community-based 
Several HPV educational interventions examined studies were delivered as part of 
community events rather than a singular intervention in a medical setting.  One randomized 
controlled trial examined participants who attended mother/daughter dinners in their Hopi 
community during which HPV educational presentations were delivered.  Participants in the 
intervention group were more likely to initiate vaccination than those in the control group, 
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although there was no significant difference between the intervention and control group related 
to completion of vaccine series (Winer et al, 2016).  The examined comic book educational 
intervention occurred at a YMCA community center in Ohio (Katz et al, 2014). 
Increased education accessibility 
Improved accessibility to educational interventions was a common factor among several 
of the reviewed studies.  The HPV educational website www.gohealthygirls.org allowed 
participants to access materials from home, and was identified as an appealing way to receive 
HPV-related education (Starling et al, 2014).  Two studies involved directly sending information 
to participants’ residences which allowed for comfortable and self-paced perusal of information.  
Tisi and colleagues (2013) mailed educational pamphlets to participants’ homes.  A randomized 
controlled trial focused on multilevel interventions including educational brochure, DVD, 
vaccine information statements (VIS), and magnet reminders were mailed to participants’ homes 
(Paskett et al., 2016).  This intervention was associated with a small positive impact: 13% of the 
intervention group received the vaccine compared with 8% of the control group.  Another 
intervention involved educational text messages sent to participants, and those in the intervention 
group demonstrated higher knowledge scores (Richman et al., 2016).  Foley and colleagues 
(2015) integrated an educational program into the community through monthly education 
sessions held at Hispanic community centers, and radio segments.   The participants in this cross-
sectional study were more likely to have knowledge of HPV, vaccination, and be willing to 
vaccinate their children.   
Interpersonal discussion 
Overwhelmingly, the greatest number of studies included in this review involved the 
opportunity for interpersonal discussion with a health educator as part of the educational 
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intervention.  Eight studies included either small group discussion, question and answer sessions, 
or one-on-one counseling as a component to the intervention, or as the sole intervention itself.  
Participants demonstrated to have increase in knowledge scores as well as increase in 
vaccination intent after participating in small group informational sessions at a black and 
minority health fair (Kester et al, 2014).  Hispanic participants who received small group 
education as a supplement to brochure education were more likely to complete the three-vaccine 
series than a group receiving brochure-education only (Parra-Medina et al, 2015).  The 
combination of language-tailored and small group HPV prevention education in a Hispanic 
population was associated with increased vaccination intention by 25% following the 
intervention. While patient-specific vaccine uptake was not measured, HPV-vaccination in the 
clinic increased from 5.4% to 18% during the intervention period (Obulaney et al, 2016).  100% 
of participants reported a Power Point and group discussion intervention as “helpful” to their 
HPV vaccine decisions (Spleen et al, 2012).  
The individuals responsible for providing the information during educational sessions 
filled various roles.  In each case, these educators were identified as either nurses, doctors, 
community health educators, or health professionals.   
Theoretical Framework 
The Health Belief Model (HBM) (Hochbaum, 1958) suggests that individuals make 
health related decisions based on their perceptions of risks and benefits of various actions or 
interventions.  Individuals are most likely to take health-promoting behaviors if they believe they 
are at risk for developing an illness and if they have faith in a particular health-promoting 
intervention.  Concepts influential upon an individuals’ health decision-making are described by 
six unique constructs.  These six constructs of the HBM include: perceived susceptibility, 
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perceived severity, perceived benefits, perceived barriers, cues to action, and self-efficacy (Glanz 
& Bishop, 2010).  The HBM provides a framework for why individuals make the decisions they 
do, and allows the provider to systematically provide education addressing each of the 
constructs.   
The aim of a toolkit is to identify and present critical information to providers which they 
may, in-turn, utilize to improve clinical care of patients.  In this project, the toolkit served to 
convey the constructs in the HBM as they relate to HPV vaccination, and addressed those 
constructs when providing health information to patients and families.  If healthcare providers 
deliver education which is grounded in the six constructs of the HBM, the education may have 
greater influence on families’ decision to vaccinate against HPV.  For example, in the realm of 
“perceived susceptibility,” many individuals misunderstand only females to be susceptible to 
HPV related diseases because of the cervical cancer risk.  The toolkit directly addressed this 
HBM realm by bringing to providers’ attention the reality of the relation of HPV to 
oropharyngeal and anal cancers, and citing this point as a key strategy when providing HPV-
vaccine education.   
As identified through the integrative review, a variety of educational materials and 
modalities were identified and provided for use in practice through the resource packet.  The 
implementation of the provider toolkit identifying critical teaching points influential to families’ 
decision-making about HPV-vaccination as well as most effective teaching modalities for high-
risk populations is based on the foundation of the HBM.  The HBM underpins the development 
of the toolkit as well because primary care providers assume that patients make healthcare 
decisions to the best of their ability, based on the information currently available to them (See 
Table 1) 
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Table 1 
Health Belief Model Constructs and Toolkit 
Construct Example How Toolkit Addressed 
Perceived Susceptibility Belief that individual is at risk for contracting 
HPV 
Clearly depict that HPV is spread through both intercourse and 
oral sex.  Both men and women are at risk.  Minority 
populations have increased incidence of HPV-related cancer. 
Perceived Severity Belief that HPV infection has negative 
consequences functionally, socially, and/or 
psychologically 
HPV infection may lead to cancers: cervical, anal, oral.  
Perceived Benefit Belief that receiving HPV-vaccine will 
protect individual from risks associated with 
HPV infection  
Vaccination before sexual activity may prevent most HPV 
infections, protect future partners, eliminate need for treatment 
for HPV-related cancers 
Perceived Barriers Belief that injection will hurt, or may cause 
adolescents to be promiscuous 
Only minor pain from injection, little risk for sensitivity.  No 
evidence that discussing vaccine may cause adolescents to 
initiate sexual activity 
Self-efficacy One individual has power to prevent spread 
of infection 
Empower patient to receive first vaccine, and give 
encouragement to return to complete series. 
Cues to action Strategies to activate readiness Provider recommendation of vaccine at same time as other 
standard 12-year vaccines, importance of vaccination prior to 
any sexual activity, language-tailored education, small-group 
informational sessions 
 
Project Design/Methods/Implementation 
The foundation of this DNP project was an integrative review of literature examining alternative 
educational modalities for at-risk patients, followed by development of a Toolkit and Resource 
Packet for implementation in practice.  Efficacy of the toolkit’s ability to enhance 
provider/patient communication about the HPV-vaccine was evaluated after presenting to the 
practice using a post-intervention survey administered via email.  The design and method 
specifics as related to the implementation site, toolkit, and resource packet development, 
analysis, and efficacy examination are described in the following sections. 
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Description of the Implementation Practice Site 
 The site for implementation of the Toolkit and Resource Packet was a pediatric primary 
care office in an urban locale north of Boston, MA.  The clinic serves a large minority 
population, with a majority Spanish speaking.  This clinic was chosen based on their diverse 
patient population.  Six practice nurses are employed in the facility, and were eligible to 
participate in this project.  Several of the nurses are multi-lingual, allowing them to 
interpersonally communicate with their patients who may not speak English without the use of 
translation services.  
 Stakeholder engagement was initiated by telephone conversation and email discussion.  
Prior to any implementation at the practice site, a student practicum request agreement was 
completed by the DNP student, UMass faculty, and nursing administration at the implementation 
site.   
Pre-Intervention Survey 
Prior to entering the implementation site, a pre-intervention survey was sent via email to 
participating nurses (see Appendix).  The goal of this survey was to assess importance of 
vaccination to the nurses’ practice, evaluate their current method of HPV specific patient 
education, and determine whether certain educational materials were needed.  Five quantitative 
categorical questions were posed and one qualitative question, where respondents could provide 
descriptive text answers.  Analysis of this data was completed by examining each question 
categorically.  Data gathered from the qualitative question was examined for themes.   
Toolkit and Resource Packet Creation and Delivery  
 The aim of the toolkit was to educate providers about key identified concepts and 
educational modalities critical to families’ decision-making surrounding HPV-vaccination.  The 
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goal was direct, precise delivery of select educational bullet-points and educational modalities 
deemed influential to families’ decision-making about the HPV-vaccine and in line with the 
HBM constructs.  The presentation and toolkit for dissemination into practice was generated 
from (a) agency guidelines and fact sheets (e.g. Centers for Disease Control and Prevention, 
Immunization Action Coalition, American Academy of Pediatrics) specifying recommendations 
aimed at educating adolescents and families about the HPV-vaccine, and (b) the findings of 
integrative review.  The documents chosen for the toolkit were factual, easy to read, and 
addressed key points families report as being barriers to HPV-vaccine acceptance. 
 Simultaneous to this project’s implementation, the Advisory Committee on Immunization 
Practices (ACIP) released a report detailing a change in recommended dosing schedule from a 
three-shot series to a two-shot series for individuals younger than 15 years.  Because of this 
recent change, information detailing the updated recommendations about using a two-dose 
schedule for HPV-vaccination was included in the toolkit as an additional element.  The ACIP 
report was released one month in advance of implementation of the toolkit, thus the complete 
Morbidity and Mortality Weekly Report detailing this update was included in the toolkit, as well 
as a verbal presentation of the critical clinical practice changes.  
The inclusion of the resource packet in this project was intended to support nurses’ ability 
to provide education to families using a method tailored to their learning needs.  The Resource 
Packet consisted of a binder of educational resources aimed at targeting a variety of different 
patients, and as demonstrated to be effective through the integrative review.  It was tailored to 
the “HPV educational needs” as identified in the nurse reported pre-intervention survey.  
Included in the Resource Packet were a variety of alternative-to-vaccine information statements 
(VIS) educational modalities, including these handouts in Spanish: one-sheet informational 
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handouts for less literate individuals, comic books about one Spanish-speaking family’s 
experience with the HPV-vaccine, and access to an educational video in Spanish.  Products were 
also supplied in English for patients who are English speaking, or for staff who required 
translation.   
Both the Toolkit and Resource packet were presented to participants by verbal in-person 
presentation by DNP student, with time for question and answer afterwards.  In addition to 
supplying the binder of Toolkit and resources, the nursing director was provided with PDF 
documents of the materials as well as a web link to the educational videos. 
Assessment of Efficacy of Intervention   
 Four weeks following implementation of presentation, toolkit, and resource packet, a 
post-intervention survey was completed by participants.  This six-question survey was intended 
to assess the effect of the intervention on the nurse’s ability to provide patient-appropriate 
educational materials. Analysis of this data consisted of systematic breakdown of each question, 
and categorical assessment of quantitative data.  Responses to the qualitative question were 
examined for themes. 
Ethics and Human Subjects Protection 
Human Subjects screening form was submitted to UMASS IRB and this project was 
determined not to be considered research under the human subject regulations (see Appendix).  
Evaluation of current research to determine what practices improves healthcare and this is 
ethically sound at its core.  Summarizing this information for delivery in a toolkit allowed 
providers access to this information in a clear and concise manner, while allowing them the 
professional freedom to implement in a way they see fit.  There are no ethical risks that have 
been identified associated with this DNP project.   
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This project has great ethical implications for health equity.  To promote health equity is 
to provide everyone with the opportunity to attain their best possible health.  Inequities are 
created whenever barriers exist that prevent individuals from accessing care. As this project 
relates to HPV-vaccination, barriers that may impede vaccination include lack of provider 
recommendation, need for further education, and provider/patient language incongruence, which 
can hinder education.  According to American Public Health Association Executive Director 
Georges Benjamin “education is central to be ready to be healthy” (Greenberg, 2015).  
Evaluating elements essential to effective education about HPV promotes health equity, because 
it identifies methods providers can utilize to promote health and prevents disease.  Evidence 
based practice reveals that HPV-vaccination prevents disease and is associated with limited risk.  
Lack of this information is a major limiting factor in a patient’s decision to receive vaccination.  
By providing this missing education in a method that is easily received by the patient, this barrier 
is mitigated.   
Great disparities exist among diseases related to HPV: they are not evenly spread out 
amongst the population.  Cervical cancer, in particular, affects a disproportionate number of 
minority women, and those from low socioeconomic classes.  Providing information to patients 
in a clear, concise manner, in a language they understand promotes health equity among groups, 
and may reduce these known disparities. Providing a more even platform for healthcare delivery 
promotes ethical practice.  
Results 
The goal of this project was to improve patient and provider communication regarding 
the HPV-vaccine.  Although an improvement in communication and thus increased patient-
awareness of the importance of HPV-vaccination may in-turn increase vaccination rates, this was 
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not measured as a part of this project and has potential as a focus of future study.  Of interest for 
this project was the perceived importance of HPV-vaccination and education to the nursing staff, 
any specific educational modalities nurses felt the patient population would benefit from at the 
project practice, and specific practice needs.  The impact of this project on meeting these specific 
educational needs and providing nurses with tools they can use in practice was assessed using 
questionnaires and qualitative information obtained during informal discussions.   
Outcomes 
Pre-intervention survey. 
Of the six nurses employed at the intervention practice, all six completed the pre-
intervention survey which focused on daily practices related to HPV education and vaccination 
at the site.  On a scale of one to five (1 - “not very important” to 5 - “very important,” ), All six 
nurses responded that they value HPV-vaccination as “very important” to adolescent health.  In 
addition, all six reported that HPV-vaccination plays a “significant” role in their routine practice.  
When asked to estimate the percentage of patients who decline HPV-vaccination, 83% of 
participants estimated 0 - 25% and 17% estimated 75-100% declined HPV-vaccination when 
offered.  In assessing what the practice currently uses for HPV-vaccine education, 100% of the 
nurses responded “provider explanation,” 67% responded “language-specific literature,” and 
17% responded “small group instruction/nurse-provided information.”  No participants 
responded “videos” or “podcasts.”  In assessing whether there were specific HPV educational 
needs at the practice, 100% of nurses responded “language-specific literature,” 33% additionally 
responded “small group instruction/nurse-provided education,” and 33% responded “videos.”   
No participants identified “podcasts” as an educational need.   
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Three participants responded to the qualitative question “please list any barriers you see 
to HPV vaccination.” Identified barriers by the nurses at their practice included: cultural beliefs; 
misinformation and “rumors” including parental concern related to the HPV-vaccination 
encouraging sexual promiscuity, the belief that HPV-vaccination is only for girls, and the worry 
that risks outweigh benefits; inconsistent provider practice related to initiating the vaccine at 11; 
and, lack of parent follow through in terms of ensuring the child/adolescent completes the series. 
Post-intervention survey. 
Three of the six participants completed the six question post-intervention survey which 
focused on the impact of this intervention on the nurses’ ability to provide patient-appropriate 
HPV educational materials. When asked to rate how helpful the information provided in the 
toolkit was to the practice, two respondents reported a 4/5 on a Likert scale (1 - “not very 
helpful” and 5 - “very helpful”).  One participant indicated the information was “very helpful.”  
Two participants responded that the provided information “somewhat” enhanced their ability to 
provide HPV education to patients, while one respondent indicated it “significantly” enhanced 
their ability to provide education.  100% of respondents reported that the information introduced 
them to HPV patient education options that are supplemental to Vaccine Information Statement 
(VIS) sheets “significantly.”  In terms of translation to practice, two nurses have not utilized the 
information at all to help answer patient’s HPV questions, while one reported utilizing the 
information a “moderate” amount.  All participants thought that HPV-vaccine education was 
“somewhat” affected by this project.   
Facilitators and barriers. 
Completion of the integrative review was limited only by DNP student time restraints.  
Acceptance and engagement by the implementation site was limited by practice time constraints, 
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nurse patient load, and personal interest in the topic of study by the nurses.  One time barrier was 
minimized by offering the surveys by email for completion and the education and toolkit at 
convenient times without interrupting clinical flow. The toolkit and resource packet were 
presented at prearranged times in person with time allowed for discussion, and the resources 
were left at the practice for staff to access when needed, allowing them to peruse at their 
convenience.  Electronic copies of all information were forwarded to participants, aiding in the 
accessibility of information. 
After delivery of the intervention, implementation of specific education suggested in the 
toolkit required only minor alterations and additions to delivery of information, during patient 
interactions that would be occurring nonetheless for clinical purposes.  In fact, implementation of 
the resource packet had the potential to save providers’ time, by allowing quick and easy access 
to appropriate patient-tailored educational materials which may otherwise be time consuming to 
unearth.  No new patients needed to be recruited for this project, nor was patient interaction an 
element of this project.  The minimal financial expenditures in the form of paper supplies for 
toolkit print-outs were absorbed by the DNP student.  
Discussion/Interpretations 
Through the literature review, a wide variety of educational interventions benefitting at-
risk groups were examined.  While vaccine acceptability and intention was frequently measured, 
few studies correlated actual vaccine uptake or vaccination rates following the interventions.  
Most studies did report that there was an increase in HPV related knowledge, vaccine 
acceptance, and even vaccine intent following implementation of the interventions.  However, 
there was no way to determine if actual successful vaccination was achieved.  Educational 
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interventions are likely to prove some benefit if the recipient is accepting of the education and 
feels invested in the topic. 
Because of the great variety of educational interventions studied in the relatively few 
number of articles available, no conclusions can be drawn about certain modalities providing 
more benefit in comparison to others.  However, opportunities for interpersonal communication 
between patient and provider was a link among many of the studies, an ideal time to address 
HPV related questions or concerns.  While one is unable to directly correlate this 
provider/patient communication with increased acceptability separate from other educational 
interventions, it was noted as a common aspect of the effective interventions.  Patient/provider 
communication is the trend that enables nurses to positively influence practice. Nurses play an 
integral role in the successful immunization of populations, both by direct administration of the 
vaccine, and by providing education.  They provide vaccine education both formally in the clinic 
and informally in the community.  By preparing nurses with streamlined education about patient-
reported learning needs, they become well-positioned to deliver this education to families 
through their daily interactions.  
The pre-intervention questionnaire provided information that allowed for the tailoring of 
the resource packet with specific tools nurses reported they may find helpful to their practice.  
This element provided some form of control and was intended to maximize the efficacy of the 
toolkit through not only meeting the identified need, but also by ensuring nurses were engaged 
and invested in the components of the resource packet.  Through this survey, most staff reported 
a desire for different language-congruent print materials, and several thought videos or small-
group nurse led discussion may be helpful.  This clear request for alternative educational 
modalities highlights nurses’ perception of opportunities for improving HPV education, and may 
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shed insight into the mechanisms that may be most helpful for the diverse patient populations 
they treat.   
Limitations of this project include the small sample which makes interpretation of the 
impact of this project limited. However, preliminary results showed promise. Of the 50% of 
participants who responded to the post-intervention survey, they unanimously felt that the 
information provided through this intervention was helpful to their practice and positively 
influenced their ability to provide HPV-education to patients.  Most notably, respondents 
reported that this project significantly improved their awareness of HPV-education options that 
could be provided in addition to the VIS sheets routinely provided to patients in this practice.  
The composition of patients served at this clinic is comprised of a large percentage of Spanish-
speaking individuals, who may directly benefit from the addition of some of these alternative 
educational strategies.  Clinician awareness is a critical component of recommending certain 
interventions, thus increasing this awareness is likely to increase the incidence with which the 
interventions are utilized with patients.   
In addition to the quantitative information obtained through surveys, qualitative 
information was obtained through question/answer sessions following implementation of the 
intervention.  Immediately following presentation of the toolkit and resource packet, informal 
discussions were held to elicit anecdotal information from participants, as well as provide further 
HPV-specific nursing education as needed.  These responses provide further insight into the 
efficacy of the toolkit, and suggestions for future applications.  All six of the participants 
provided feedback about the perceived usefulness of the tools, as well as suggestions for how to 
disseminate the data to patients, and other healthcare providers.   
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The overall consensus among staff about the education toolkit and resource packet was 
positive, particularly for future applicability of the various language-congruent resources.  
Overwhelmingly, participants reported that the patient population of the clinic would be 
especially receptive to certain Spanish handouts provided, highlighting that they may be easier 
for patients to read and understand then what is routinely offered currently in the clinic.  Two 
staff members commented on the visually appealing one-page informative sheet as being 
particularly beneficial to families in the practice with limited literacy.  Respondents indicated 
through the post-intervention survey their perception that HPV-vaccine education was 
“somewhat” affected by this project.  Clearly, nurse awareness of different educational strategies 
was increased, however actual implementation at the patient level was infrequent.  The reported 
“somewhat” degree of efficacy presents opportunity for future examination to determine which 
specific aspects of HPV-education were realized through this project. 
While only two nurses reported via the pre-intervention survey that they would find 
Spanish videos helpful for patient education, during discussion the nurses unanimously reported 
their perception that videos may be a helpful tool. One participant did suggest one possible 
occasion when videos could be utilized: during the time patients are waiting for the providers to 
come to the exam room.  However, she further explained that the need for additional HPV 
education is typically not realized until after the conclusion of the provider visit.  All other 
participants believed that time constraints in the clinic would prevent utilization of video 
education.  The use and efficacy of videos for teaching thus deserves further study. 
Several nurses did comment on their personal sense of limited ability to assess the 
patient’s need for additional educational resources based on their assumption that the providers 
frequently supplied as much educational information as the patients needed.  There were few 
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instances where families directed vaccine questions to nurses rather than the provider.  In 
general, the nurses were eager to identify resources their patients would benefit from and willing 
to present these additional resources to those patients in need; however, they felt that overall 
patients were accepting of HPV-vaccination after the recommendation by the provider. 
Despite the reported belief of the participants for this project being helpful and influential 
to the practice of providing HPV-education to patients, respondents reported utilizing the 
information either “moderately”, or “not at all.”  It is important to note that the HPV vaccination 
rate for this clinic is higher than the state average which implies that at some point a majority of 
patients are being offered vaccination.  The reported current practice at this facility is 
recommendation of the HPV-vaccine equally and in the same way as the other adolescent 
immunizations.  This practice is in-line with evidence-based strategies suggested by the CDC for 
increasing HPV vaccination rates and implementing best evidence-based recommendations 
aimed at improving rates. One nurse reported her beliefs that because this community population 
is generally underserved, the patients are eagerly receptive to the medical care that is offered, 
thus less likely to decline immunizations that are recommended.   
In different clinical settings, standing orders have been implemented as a strategy to 
improve HPV-vaccination rates. A Standing Order is a protocol enabling assessment of 
vaccination status and subsequent administration (if needed) without a direct physician’s order.  
In the case of standing orders, immunizations may be administered during an office visit by 
nursing staff prior to the patient meeting with the provider.  In Massachusetts, LPNs and RNs 
may administer vaccines under standing orders, and the Massachusetts Department of Public 
Health provides a model for implementing this in clinic (Commonwealth of Massachusetts, 
2017).  This strategy may free up physician and Nurse Practitioner time through placing some 
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the vaccine education responsibilities on nursing staff, who also administer the vaccines.  In 
settings where Standing Orders are in place, it is plausible that the nursing staff may more 
thoroughly utilize the information presented through this project because of the increased 
responsibility to provide HPV vaccine education to patients.   
During discussion, several participants requested additional information about the recent 
recommendation change from a three-dose HPV series to two doses.  While educational 
materials were supplied as part of the toolkit, many participants were not aware of the evidence 
resulting in the recommendation modification.  This request for information suggests the need to 
further educate clinicians about the evidence behind the change in recommendation.  
Overwhelmingly, participants were optimistic that this recent change will increase vaccine 
acceptance and successful vaccination rates.   
Results from the information obtained through questionnaire and discussion indicates that 
the toolkit is an effective intervention to raise awareness about various educational mechanisms 
that can be utilized with different patient populations.  The in-person delivery of the material was 
well-received and effective, allowing for further exploration of the topic, as well as the 
opportunity for further staff education regarding current immunization guideline changes.  Based 
on the information available, this project had limited sustained effect on the delivery of 
information, as few nurses reported utilizing the information for patient education one month 
following implementation.  To further examine this toolkit as a method for increasing awareness 
and improving communication between patients and nurses, this could be implemented across a 
larger sample and include diverse populations ethnically, racially and socioeconomically.  
Additionally, implementation of this project in a setting where nursing staff consistently provide 
more vaccine education could prove beneficial. 
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Suggestions and future recommendations. 
The interest and engagement by the nurses, as well as their contribution about perceived 
patient preferences for educational interventions demonstrates that nurses play an integral role in 
educating about HPV-disease and vaccination.  Their interest and engagement during the post-
intervention discussion sessions clearly depicts an interest in the subject matter, and a willing 
receptive audience.  The wide variety of practice settings and integration of nurses into the 
community presents the opportunity to promote sustained patient education through first 
educating this ready and willing audience of health professionals.   
This project may be expanded in the future through distribution of the toolkit and 
resource packet to a variety of clinic settings, including school based health clinics, and to 
providers who are integral to delivery of HPV-vaccine information.  While the DNP student 
shared the purpose of this project and had informal discussion with several physicians and nurse 
practitioners at the implementation site, they were not direct recipients of the intervention.  
Seeking out practices where nurses are the primary educators prior to administration of 
vaccinations such as settings where Standing Orders are implemented could serve to have a 
greater impact.  Additionally, delivering this toolkit and resource packet directly to the providers 
who place orders for the vaccine (physicians, nurse practitioners, and physician assistants) may 
also have beneficial impact.  
Conclusion 
HPV remains a common sexually transmitted viral infection, affecting an estimated 79 
million Americans currently.  Despite the availability and recommendations of immunization, 
rates of HPV-vaccination remain low.  The risk of future HPV related cancers is increased for 
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individuals who remain unvaccinated against HPV, with certain minority populations at 
increased risk for developing these related cancers.   
The purpose of the DNP project was to evaluate the efficacy of educational modalities at 
providing HPV-vaccine information to at-risk populations, and to provide a toolkit and resource 
packet aimed at enhancing provider/patient communication about the HPV-vaccine in addition to 
providing various options for educational strategies. 
Through integrative review, the common theme of patient/provider communication was 
identified as an integral component to effective HPV-education, and nurses were provided with a 
toolkit and resource packet of various patient educational materials to utilize during their patient 
education encounters.  Through survey questionnaire and informal discussion with participants, 
the impact of this intervention and toolkit was analyzed.  Based on results of the questionnaire 
and discussion, this toolkit was determined to be an effective way to introduce nurses to a variety 
of HPV educational materials they may find useful with their patient populations.  Nurses were 
interested and engaged in the topic and invested in identifying educational materials their 
patients may benefit from.  However, participants at the study site infrequently utilized the 
educational materials with patients one month following intervention which merits further 
consideration.  The project’s impact on patient/provider communication about HPV would 
benefit from future study specifically implementing the toolkit on a broader scale, in a setting 
with already identified gaps in staff awareness of alternative educational materials.  
Dissemination of this project is multifactorial, and encompasses three settings: the 
community, with other professionals in practice, and with scholars. While this project directly 
examined the impact of a toolkit on nurses’ ability to provide alternative educational modalities 
to high-risk populations, outside of the clinic setting the DNP student educated her local 
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community on a more basic level.  Through informal daily interaction with community members 
throughout the duration of this project, HPV infection and vaccine education was discussed.  A 
personal observation of friends, colleagues, and parents’ skepticism about the HPV-vaccine and 
the resulting hesitation to have their children vaccinated inspired the DNP student to pursue this 
project.  Engaging in social conversation with laypersons and networking with community 
members fosters the education of immediate community members.  Involvement in professional 
conferences and the Massachusetts HPV/cervical cancer awareness coalition presents 
opportunities to share the results of this project.  Dissemination at the community level cannot be 
trivialized.  Conversation increases awareness of the importance of the vaccine, and risks 
associated with acquiring the disease.  Normalizing the conversation about HPV and related 
cancers may inspire individuals to be comfortable to have further conversation with 
their healthcare providers.  Finally, discussions about the availability of educational materials 
may inspire people who would benefit from such materials to seek them out, or acquire them for 
family members. 
While completing the project at the implementation site, healthcare professionals 
including nurses, physicians, and management were impacted.  The goal was to increase medical 
professionals’ awareness of the great variety of alternative educational materials for high-risk 
HPV individuals, as well as the ease of accessing this information.  By increasing providers’ 
awareness, the hope is they will in-turn use these materials with their patients, who will benefit 
by an increased understanding of the information.  By providing electronic versions of the 
variety of educational materials, as well as direct access to the videos, the goal was 
sustainability: allowing staff access to the information, as well as an easy ability to share with 
others.   
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Results of the integrative review are important, particularly because it highlights the 
critical role providers play in educating patients about the HPV vaccine.  Because of the limited 
generalizability of findings to the general population, conducting this project on a larger scale 
would be suggested prior publication of any resulting information. Further dissemination plans 
include directly sharing the results from the analysis determining the efficacy of the toolkit and 
resource packet implementation with leadership from the implementation site.  Scholarly 
dissemination will be further realized through poster presentation during UMass Amherst 
Nursing Scholar day with student colleagues and academic faculty.   
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Appendices 
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Pre-Intervention Survey 
 
1. How valuable do you believe HPV vaccination is to adolescent health? 
 
1 - Not very important 
2  
3 - Somewhat important 
4 
5 - Very important 
 
2. To what extent is HPV vaccination a routine part of your practice? 
 
[ ] Not at all 
[ ] Somewhat 
[ ] Moderate 
[ ] Significant 
 
3. What percentage of patients decline HPV vaccination? (estimate) 
 
[ ] 0-25% 
[ ] 25-50% 
[ ] 50-75% 
[ ] 75-100% 
 
4. What do you currently use for HPV vaccine education? (check all appropriate) 
 
[ ] Provider Explanation 
[ ] Small group instruction/nurse-provided information 
[ ] Language specific literature 
[ ] Videos 
[ ] Podcasts 
 
5. Are there specific HPV educational needs? (check all appropriate) 
 
[ ] Small group instruction/nurse-provided education 
[ ] Language specific literature 
[ ] Videos  
[ ] Podcasts 
 
6. Please list any barriers you see to HPV vaccination 
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Post-Intervention Survey 
 
 
1. How helpful was the information provided in the toolkit for your practice? 
 
[ ] Not at all 
[ ] Somewhat 
[ ] Moderate 
[ ] Significant 
 
2. To what extent did the information provided enhance your delivery of HPV education 
to patients?  
 
[ ] Not at all 
[ ] Somewhat 
[ ] Moderate 
[ ] Significant 
 
3. To what extent did the information provided introduce you to HPV patient education 
options that are alternative to VIS sheets? 
 
[ ] Not at all 
[ ] Somewhat 
[ ] Moderate 
[ ] Significant 
 
4. Have you utilized the provided information to help answer patient’s HPV related 
questions? 
 
[ ] Not at all 
[ ] Somewhat 
[ ] Moderate 
[ ] Significant 
 
5. Do you think HPV vaccine education was affected at all by this project? 
 
[ ] Not at all 
[ ] Somewhat 
[ ] Moderate 
[ ] Significant 
 
6. Please list any comments or suggestions 
 
 
Done 
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Introduction
Vaccination against human papillomavirus (HPV) is rec-
ommended to prevent HPV infections and HPV-associated 
diseases, including cancers. Routine vaccination at age 11 or 
12 years has been recommended by the Advisory Committee 
on Immunization Practices (ACIP) since 2006 for females 
and since 2011 for males (1,2). This report provides recom-
mendations and guidance regarding use of HPV vaccines and 
updates ACIP HPV vaccination recommendations previously 
published in 2014 and 2015 (1,2). This report includes new 
recommendations for use of a 2-dose schedule for girls and 
boys who initiate the vaccination series at ages 9 through 
14 years. Three doses remain recommended for persons who 
initiate the vaccination series at ages 15 through 26 years and 
for immunocompromised persons.
Background
HPV infection causes cervical, vaginal, and vulvar cancers 
in women; penile cancers in men; and oropharyngeal and anal 
cancers as well as genital warts in both men and women (3). 
Three HPV vaccines are licensed for use in the United States. 
All are noninfectious. Quadrivalent and 9-valent HPV vac-
cines (4vHPV and 9vHPV, Gardasil and Gardasil 9, Merck 
and Co, Inc., Whitehouse Station, New Jersey) are licensed for 
use in females and males aged 9 through 26 years (1). Bivalent 
HPV vaccine (2vHPV, Cervarix, GlaxoSmithKline, Rixensart, 
Belgium) is licensed for use in females aged 9 through 25 years 
(1). As of late 2016, only 9vHPV is being distributed in the 
United States. The majority of all HPV-associated cancers are 
caused by HPV 16 or 18, types targeted by all three vaccines. 
In addition, 4vHPV targets HPV 6 and 11, types that cause 
genital warts. 9vHPV protects against these and five additional 
types: HPV 31, 33, 45, 52, and 58. All three vaccines have been 
approved for administration in a 3-dose series at intervals of 
0, 1 or 2, and 6 months. In October 2016, after considering 
new clinical trial results (4), the Food and Drug Administration 
(FDA) also approved 9vHPV for use in a 2-dose series for 
girls and boys aged 9 through 14 years (5). In October 2016, 
ACIP recommended a 2-dose schedule for adolescents initiat-
ing HPV vaccination in this age range. This report provides 
recommendations for use of 2-dose and 3-dose schedules for 
HPV vaccination.
Methods
During November 2015–October 2016, the ACIP HPV 
Vaccines Work Group held monthly telephone conferences 
to 1) review and evaluate the quality of the evidence assessing 
immunogenicity, efficacy, and postlicensure effectiveness of a 
2-dose schedule; 2) consider benefits and harms of a 2-dose 
schedule; 3) weigh the variability in the values and preferences 
of patients and providers for a 2-dose schedule; and 4) examine 
health economic analyses. During teleconferences, summaries 
of findings were presented for Work Group discussion.
A systematic review was conducted to identify studies 
involving human subjects* that reported primary data on 
any important or critical health outcomes related to HPV 
vaccination† after 2 doses of 9vHPV, 4vHPV, or 2vHPV, 
administered at an interval of 0 and ≥6 months (±4 weeks) to 
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Recommendations for use of vaccines in children, adolescents 
and adults are developed by the Advisory Committee on 
Immunization Practices (ACIP). ACIP is chartered as 
a federal advisory committee to provide expert external 
advice and guidance to the Director of the Centers 
for Disease Control and Prevention (CDC) on use of 
vaccines and related agents for the control of vaccine-
preventable diseases in the civilian population of the United 
States. Recommendations for use of vaccines in children 
and adolescents are harmonized to the greatest extent 
possible with recommendations made by the American 
Academy of Pediatrics (AAP), the American Academy of 
Family Physicians (AAFP), and the American College of 
Obstetricians and Gynecologists (ACOG). Recommendations 
for routine use of vaccines in adults are harmonized with 
recommendations of AAFP, ACOG, and the American 
College of Physicians (ACP). ACIP recommendations 
approved by the CDC Director become agency guidelines 
on the date published in the Morbidity and Mortality 
Weekly Report (MMWR). Additional information about 
ACIP is available at https://www.cdc.gov/vaccines/acip.
* No primary data on special populations or medical conditions, including 
immunocompromising conditions, were available for 2-dose intervals and age 
ranges specified.
† No primary data on other important and critical outcomes, including genital warts, 
precancers, oropharyngeal cancer, anal cancer, cervical cancer, vaginal/vulvar cancer, 
and penile cancer, were available for 2-dose intervals and age ranges specified.
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persons aged 9 through 14 years. The review focused on this 
age group given available 2-dose trial data for 9vHPV (4). 
Immunogenicity outcomes of interest were seroconversion, 
geometric mean titers (GMTs), or antibody avidity. Studies 
were excluded if they lacked a comparison group in which 
efficacy of 3 doses of HPV vaccine against clinical endpoints 
was demonstrated in clinical trials (e.g., females aged 15 
through 26 years).§ Evidence regarding a 3-dose schedule for 
HPV vaccine was reviewed previously (1,2).
Quality of evidence was evaluated using the Grading of 
Recommendations Assessment, Development and Evaluation 
(GRADE) approach. Detailed methods and GRADE tables 
can be found online (6). Other studies from the search and 
from the broader literature informed additional expert guid-
ance that extended beyond the research question addressed 
formally via GRADE analysis (7). Evidence was reviewed by 
the Work Group, summarized, and publicly presented at the 
February and June 2016 ACIP meetings. CDC vaccine rec-
ommendations are developed using the GRADE framework 
(8). Proposed recommendations were presented, and after a 
public comment period, were approved unanimously¶ by the 
voting ACIP members at the October 2016 ACIP meeting.
Summary of Key Findings
Immunogenicity. In the 9vHPV clinical trial that was the 
basis for FDA approval of a 2-dose series, participants were 
girls and boys aged 9 through 14 years, compared with young 
females aged 16 through 26 years (4). Among 1,377 partici-
pants, ≥97.9% seroconverted to all nine vaccine-preventable 
HPV types by 4 weeks after the last dose. For girls and boys 
who received 2 doses of 9vHPV 6 months apart (0, 6 month 
schedule) or 12 months apart (0, 12 month schedule), non-
inferiority criteria were met for seroconversion and GMTs. 
Furthermore, GMTs were significantly higher for all 9vHPV 
types among persons aged 9 through 14 years who received 2 
doses compared with females aged 16–26 years who received 
3 doses (0, 2, 6 month schedule). Six additional studies found 
similar results for 4vHPV and 2vHPV (6). Immunogenicity 
was found to be noninferior with 2 doses in persons aged 9 
through 14 years compared with 3 doses in a group in which 
clinical efficacy was demonstrated (GRADE evidence type 3).
Efficacy and effectiveness. Although efficacy and postlicen-
sure effectiveness studies were reviewed, none met the inclusion 
criteria detailed above. The prelicensure HPV vaccine efficacy 
trials were conducted with 3-dose series; post hoc analyses con-
ducted with data from some of these trials found high efficacy 
against infection among vaccinees who received 2 doses and 
those who received 3 doses (9,10). A large study comparing 
2 doses with 3 doses also suggested similar efficacy against 
infection (11). Postlicensure effectiveness studies have found 
lower effectiveness against various HPV-associated outcomes 
among vaccinees who received 2 doses compared with those 
who received 3 doses, but methodologic challenges with these 
studies limit interpretation of the findings.**
Duration of protection. Through 10 years of follow-up 
from clinical trials, no evidence of waning protection after 
a 3-dose series of HPV vaccine has been found (1). Because 
antibody kinetics are similar with 2-dose and 3-dose series, 
duration of protection is also expected to be long-lasting after 
a 2-dose series (12,13).
Health impact and cost-effectiveness modeling. 
Population-level effectiveness and cost-effectiveness of 2-dose 
and 3-dose schedules of 9vHPV in the United States have been 
modeled (14). Assuming both efficacy and duration of protec-
tion are similar with either schedule, a 2-dose series would be 
cost-saving and have similar population impact to a 3-dose 
series. Even if duration of protection is 20 years for a 2-dose 
series and lifelong for a 3-dose series, additional benefits of 
a 3-dose series would be relatively small, and a 2-dose series 
would be more cost-effective (14).
Rationale
HPV vaccines are highly effective and safe, and a powerful pre-
vention tool for reducing HPV infections and HPV-associated 
cancers (1,2). Based on the available immunogenicity evidence, 
a 2-dose schedule (0, 6–12 months) will have efficacy equivalent 
to a 3-dose schedule (0, 1–2, 6 months) if the HPV vaccination 
series is initiated before the 15th birthday (GRADE evidence 
type 3) (6). ACIP recommends a 2-dose schedule for HPV vac-
cination of girls and boys who initiate the vaccination series at 
ages 9 through 14 years (Category A recommendation).
Recommendations
Routine and catch-up age groups. ACIP recommends 
routine HPV vaccination at age 11 or 12 years. Vaccination 
can be given starting at age 9 years. ACIP also recommends 
vaccination for females through age 26 years and for males 
through age 21 years who were not adequately vaccinated 
previously. Males aged 22 through 26 years may be vaccinated. 
(See also: Special populations, Medical conditions)
Dosing schedules. For persons initiating vaccination before 
their 15th birthday, the recommended immunization sched-
ule is 2 doses of HPV vaccine. The second dose should be 
§ Studies were excluded when 2-dose interval was not ≥5 months.
¶ Twelve votes to none, with one recusal.
 ** In studies conducted in the setting of a 3-dose HPV vaccine recommendation 
or policy, many 2-dose recipients received HPV vaccine doses at a 1–2 month 
interval; in addition, 2-dose recipients differed from 3-dose recipients in ways 
that suggested differences in HPV exposure.
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administered 6–12 months after the first dose (0, 6–12 month 
schedule)†† (Table).
For persons initiating vaccination on or after their 15th 
birthday, the recommended immunization schedule is 3 doses 
of HPV vaccine. The second dose should be administered 
1–2 months after the first dose, and the third dose should be 
administered 6 months after the first dose (0, 1–2, 6 month 
schedule)§§ (Table).
Persons vaccinated previously. Persons who initiated vac-
cination with 9vHPV, 4vHPV, or 2vHPV before their 15th 
birthday, and received 2 doses of any HPV vaccine at the 
recommended dosing schedule (0, 6–12 months), or 3 doses 
of any HPV vaccine at the recommended dosing schedule (0, 
1–2, 6 months), are considered adequately vaccinated.
Persons who initiated vaccination with 9vHPV, 4vHPV, or 
2vHPV on or after their 15th birthday, and received 3 doses 
of any HPV vaccine at the recommended dosing schedule, are 
considered adequately vaccinated.
9vHPV may be used to continue or complete a vaccination 
series started with 4vHPV or 2vHPV.
For persons who have been adequately vaccinated with 
2vHPV or 4vHPV, there is no ACIP recommendation regard-
ing additional vaccination with 9vHPV.
Interrupted schedules. If the vaccination schedule is inter-
rupted, the series does not need to be restarted. The number 
of recommended doses is based on age at administration of 
the first dose.
Special populations. For children with a history of sexual 
abuse or assault, ACIP recommends routine HPV vaccination 
beginning at age 9 years.
For men who have sex with men,¶¶ ACIP recommends 
routine HPV vaccination as for all males, and vaccination 
through age 26 years for those who were not adequately vac-
cinated previously.
For transgender persons, ACIP recommends routine 
HPV vaccination as for all adolescents, and vaccination 
through age 26 years for those who were not adequately 
vaccinated previously.
Medical conditions. ACIP recommends vaccination with 3 
doses of HPV vaccine (0, 1–2, 6 months) for females and males 
aged 9 through 26 years with primary or secondary immuno-
compromising conditions that might reduce cell-mediated 
or humoral immunity,*** such as B lymphocyte antibody 
deficiencies, T lymphocyte complete or partial defects, HIV 
infection, malignant neoplasms, transplantation, autoimmune 
disease, or immunosuppressive therapy, because immune 
response to vaccination might be attenuated (Table) (7).
Contraindications and precautions. Contraindications 
and precautions, including those related to pregnancy, are 
unchanged from previous recommendations (1,2). Adverse 
events occurring after administration of any vaccine should 
be reported to the Vaccine Adverse Event Reporting System 
(VAERS). Reports can be submitted to VAERS online, by fax, 
or by mail. Additional information about VAERS is available by 
telephone (1-800-822-7967) or online (https://vaers.hhs.gov).
TABLE. Recommended number of doses and intervals for human papillomavirus (HPV) vaccine, by age at series initiation and medical conditions — 
United States, 2016
Population
Recommended number of 
HPV vaccine doses
Recommended interval 
between doses
Persons initiating HPV vaccination at ages 9 through 14 years,* except 
immunocompromised persons†
2 0, 6–12 months§
Persons initiating HPV vaccination at ages 15 through 26 years¶ and 
immunocompromised persons† initiating HPV vaccination at ages 9 through 26 years
3 0, 1–2, 6 months**
 * ACIP recommends routine HPV vaccination for adolescents at age 11 or 12 years; vaccination may be given starting at age 9 years.
 † Persons with primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral immunity (see also: Medical conditions)
 § In a 2-dose schedule of HPV vaccine, the minimum interval between the first and second doses is 5 months.
 ¶ For persons who were not adequately vaccinated previously, ACIP recommends vaccination for females through age 26 years and for males through age 
21 years; males ages 22 through 26 years may be vaccinated. Vaccination is recommended for some persons aged 22 through 26 years; see Medical conditions 
and Special populations.
 ** In a 3-dose schedule of HPV vaccine, the minimum intervals are 4 weeks between the first and second doses, 12 weeks between the second and third doses, and 
5 months between the first and third doses.
 †† In a 2-dose schedule of HPV vaccine, the minimum interval between the first 
and second doses is 5 months. If the second dose is administered after a shorter 
interval, a third dose should be administered a minimum of 12 weeks after 
the second dose and a minimum of 5 months after the first dose.
 §§ In a 3-dose schedule of HPV vaccine, the minimum intervals are 4 weeks 
between the first and second doses, 12 weeks between the second and third 
doses, and 5 months between the first and third doses. If a vaccine dose is 
administered after a shorter interval, it should be readministered after another 
minimum interval has elapsed since the most recent dose.
 ¶¶ Including men who identify as gay or bisexual, or who intend to have sex 
with men.
 *** The recommendation for a 3-dose schedule of HPV vaccine does not apply 
to children aged <15 years with asplenia, asthma, chronic granulomatous 
disease, chronic liver disease, chronic lung disease, chronic renal disease, 
central nervous system anatomic barrier defects (e.g., cochlear implant), 
complement deficiency, diabetes, heart disease, or sickle cell disease.
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1FACT 
Scientists from both the CDC and the FDA continue to monitor and report any adverse events 
and side effects related to HPV vaccines. Monitoring in 2009 revealed that most side effects 
related to the vaccine were mild and were similar to those seen with any other vaccine. Several 
studies from 2011-2015 looking at more than four million women and girls who have received the 
vaccine show that there is no relationship between HPV vaccines and autoimmune disorders, 
blood clots, or other serious disorders.1
TALKING POINT:  More than 200 million doses of vaccine have been distributed worldwide, with 
more than 80 million doses in the US. While the safety of these vaccines are continually monitored 
in 80 countries, no safety concerns have been identified. All vaccines have side effects, but 
reactions caused by HPV vaccines have been mostly mild and similar to those from other vaccines.2
The HPV vaccine is safe.
FACT  3
Claims of HPV vaccine-induced infertility are anecdotal and not backed by research or clinical 
trials. The HPV vaccine can actually help protect fertility by preventing gynecological problems 
related to the treatment of cervical cancer. It’s possible that the treatment of cervical cancer 
could leave a woman unable to have children. It’s also possible that treatment for cervical 
pre-cancer could put a woman at risk for problems with her cervix, which could cause preterm 
delivery or other problems.3
TALKING POINT: There are no data to suggest that getting the HPV vaccine will have a negative 
effect on future fertility. In fact, getting vaccinated and protecting against cervical cancer can 
help protect a woman’s ability to get pregnant and have healthy babies.3 
The HPV vaccine does NOT cause fertility issues.2
The VACs project is supported in part by CDC Cooperative Agreement Number 1H23IP000953-01. 
FACT  4
HPV vaccines contain ingredients that have been proven to be safe. Like the hepatitis B and Tdap 
vaccines, HPV vaccines contain aluminum, which boosts the body’s immune response to the vaccine. 
In addition to certain vaccines, aluminum is found in breast milk, infant formula,  antacids, and 
numerous foods and beverages, including fruits and vegetables, seasonings, flour, cereals, nuts, 
dairy products, and honey. Typical adults ingest 7 to 9 milligrams of aluminum per day, whereas the 
HPV vaccines contain .225 milligrams of aluminum per dose.4  These vaccines, like other vaccines for 
children and adolescents, do not contain thimerosal (a preservative that contains mercury).6
TALKING POINT: Given the quantities of aluminum we are exposed to on a daily basis, the quantity 
of aluminum in vaccines is miniscule. Aluminum-containing vaccines have been used for decades 
and have been given to more than 1 billion people without problems. In spring 2000, the National 
Vaccine Program Office reviewed aluminum exposure through vaccines and determined that 
no changes to vaccine recommendations were needed based on aluminum content. The Global 
Advisory Committee on Vaccine Safety, part of the World Health Organization, has also reviewed 
studies and found no evidence of health risks that would require changes to vaccine policy.4
The HPV vaccine does NOT contain harmful ingredients. 3
FACT  5
Vaccines are for prevention, not treatment, so they only work if given before coming in contact 
with a virus. Research also shows that younger people create more antibodies to the vaccine 
than those in their late teens.5 
Studies have shown that HPV vaccination is not associated with changes in sexual behavior. Age 
of onset of sexual activity, incidence of STIs, and rates of pregnancy have all been shown to be 
similar in vaccinated girls compared to unvaccinated girls.7,9,10  
 
TALKING POINT: People are vaccinated well before they’re exposed to an infection (i.e., measles 
and the other recommended childhood vaccines). Similarly, they should be vaccinated before 
they are exposed to HPV. Also, the HPV vaccine produces a higher immune response in preteens 
than it does in older teens.5
HPV is so common that almost everyone will be exposed at some point in their lives. So even if 
your child delays sexual activity until marriage, or only has one partner in the future, they could 
still be exposed if their partner has been exposed.8
Studies have shown there’s no correlation between receiving the HPV vaccine and increased 
rates of (or earlier engagement in) sexual activity.9
The HPV vaccine is necessary, regardless of 
sexual activity.4
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FACT  6
Both males and females can get HPV. It’s very common; the CDC estimates that between 80-90% 
of sexually active people will be infected with at least one type of HPV in their lifetime.11
Although cervical cancer is currently the most common type of cancer caused by HPV, persistent 
infection also causes cancers of the base of the tongue and tonsils. These cancers are becoming 
more common, especially among men, and may be more common than cervical cancer by 2020. 
HPV can also cause penile and anal cancers in men. The HPV vaccine provides protection against 
most of the genital cancers in men caused by HPV infection.5 
TALKING POINT: HPV vaccination is strongly recommended for boys and girls. Vaccination helps 
protect boys from getting infected with the most common types of HPV than can cause cancers of 
the throat, penis, and anus; it also helps prevent most genital warts. In addition, when boys are 
vaccinated, they are less likely to spread HPV to their current and future partners.3
The HPV vaccine is for boys and girls. 5
FACT  7
In studies that led to the approval of HPV vaccines, the vaccines provided nearly 100% 
protection against persistent cervical infections with HPV types 16 and 18, plus the pre-cancers that 
those persistent infections can cause. In addition, a clinical trial of HPV vaccines in men indicated 
that they can prevent anal pre-cancers caused by persistent infection and genital warts.8
HPV-associated cancers can take decades to develop, and the vaccines have not been in use long 
enough to produce studies comparing cancer rates. Advanced pre-cancers are universally accepted 
markers for cancers.  
TALKING POINT: The vaccine has been proven, through numerous studies, to prevent the cell 
changes and infections that correspond with multiple HPV-associated cancers.  
In addition, population studies in the US and other countries that have introduced the HPV 
vaccine have shown a significant reduction in abnormal Pap test results14,15 and genital warts.16,17
The HPV vaccine is effective and prevents cancer.6
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FACT  8
Studies have shown many parents (37%) have no prior knowledge about the vaccine before 
their child’s provider educates them about it. Knowledge varies across racial/ethnic groups,  
socioeconomic status, and geographic areas.12  Studies have also shown that parents value the 
HPV vaccine equally with other adolescent vaccines.18 In addition, parents want to prevent  
cancer in their children.
TALKING POINT: A quality provider recommendation is the single best predictor of vaccination.2 
Recent studies show that a patient who receives a provider recommendation is four to five times 
more likely to receive the HPV vaccine.19,20
Many parents do not know about the HPV vaccine  
and benefit from a quality provider recommendation.7
FACT  9
Ongoing studies have found that those who received the vaccine continue to have antibodies  
to the virus, providing long-term protection against infections and pre-cancers. There is no  
indication that they will decrease over time, but studies continue.13
TALKING POINT: Studies continue to monitor how long the vaccine protects against HPV 
infections and cancer. Protection has been shown to last at least 10 years with no signs of the 
protection weakening.
The effectiveness of the HPV vaccine does not 
decrease over time. 8
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Talking to Parents about HPV Vaccine  
Recommend HPV vaccination in the same way and on the same day as all adolescent vaccines. 
You can say, “Now that your son is 11, he is due for vaccinations today to help protect him from meningitis, HPV cancers, and pertussis.” Remind parents of the follow-up shots their child will need and ask them to make appointments before they leave. 
Why does my 
child need 
HPV vaccine? 
HPV vaccine is important because 
it prevents infections that can 
cause cancer. That’s why we need 
to start the shot series today. 
Is my child really 
at risk for HPV? 
HPV is a very common infection 
in women and men that can cause 
cancer. Starting the vaccine series 
today will help protect your child 
from the cancers and diseases 
caused by HPV. 
Why do they need 
HPV vaccine at 
such a young age? 
Like all vaccines, we want to give 
HPV vaccine earlier rather than 
later. If you wait, your child may 
need three shots instead of two. 
I’m worried about 
the safety of 
HPV vaccine. Do 
you think it’s safe? 
Yes, HPV vaccination is very safe. 
Like any medication, vaccines can 
cause side effects, including pain, 
swelling, or redness where the shot 
was given. That’s normal for HPV 
vaccine too and should go away in a
day or two. 
Sometimes kids faint after they get 
shots and they could be injured if 
they fall from fainting. We’ll protect
your child by having them stay 
seated after the shot. 
 
 
Would you get 
HPV vaccine for 
your kids? 
Yes, I gave HPV vaccine to  
my child (or grandchild, etc.) 
when he was 11, because it’s 
important for preventing cancer. 
Why do boys need
HPV vaccine? 
 
HPV vaccination can help prevent 
future infection that can lead to 
cancers of the penis, anus, and 
back of the throat in men. 
What diseases are 
aused by HPV? 
Some HPV infections can 
cause cancer—like cancer c
of the cervix or in the back 
of the throat—but we can 
protect your child from these 
cancers in the future by getting 
the first HPV shot today. 
How do you know 
the vaccine works? 
Studies continue to prove 
HPV vaccination works 
extremely well, decreasing 
the number of infections and 
HPV precancers in young people 
since it has been available. 
I’m worried my child 
will think that getting 
this vaccine makes it 
OK to have sex. 
Studies tell us that getting 
HPV vaccine doesn’t make 
kids more likely to start 
having sex. I recommend 
we give your child her first 
HPV shot today. 
Can HPV vaccine 
cause infertility 
in my child? 
There is no known link 
between HPV vaccination 
and the inability to have 
children in the future. 
However, women who develop an 
HPV precancer or cancer could 
require treatment that would limit 
their ability to have children. 
What vaccines are 
actually required?
I strongly recommend each
of these vaccines and so 
do experts at the CDC and 
major medical organizations. School 
entry requirements are developed 
for public health and safety, but 
don’t always reflect the most 
current medical recommendations 
for your child’s health. 
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Massachusetts Department of Public Health 
Massachusetts Chapter, American Academy of Pediatrics 
  September 2016 
Massachusetts HPV Initiative: 
Raising HPV Immunization Rates to Prevent HPV-Related Cancers  
    
                                                                                                                      
THE CURRENT PROBLEM           
Even though the HPV vaccine can prevent cancer, immunization rates remain very low among female and 
male adolescents in our state.  Missed opportunities for HPV vaccination may result in serious 
consequences. The CDC, AAP and AAFP recommend that all 11-12 year-olds receive HPV, meningococcal, 
and Tdap vaccines at the same time. 
 
WHAT CAN PROVIDERS DO? 
The most significant factor in parents' decision to vaccinate their children with HPV vaccine is a strong, 
routine recommendation from the child's healthcare provider. Research shows that simply changing the 
wording used to introduce the HPV vaccine makes a tremendous difference. 
 
HELPFUL STRATEGIES 
• Talk about HPV vaccination as cancer prevention. Cancer prevention is important to 
parents so remind them that certain HPV types can cause not only cervical cancer, but also 
anal, penile, vaginal, vulvar, and oropharyngeal cancers.  
• Recommend the HPV vaccine the same way and on the same day as other vaccines. 
 
 
 
 
 
 
 
OTHER RESOURCES 
CDC You are the Key to Cancer Prevention Clinician Website: http://www.cdc.gov/hpv/hcp/  
MA Chapter, American Academy of Pediatrics (MCAAP) HPV Website: http://mcaap.org/immunization-hpv/  
 
Contact Rebecca Vanucci (rebecca.vanucci@state.ma.us), MDPH Immunization Outreach Coordinator, for more information. 
“Now that your child is 11, they are due for three vaccines that are really important 
for all kids their age. They will help protect against meningitis, HPV cancers, and 
pertussis. We will be giving these at the end of the visit today.” 
 
 
WHAT YOU NEED TO KNOW 
ABOUT HPV AND HPV-RELATED 
CANCERS 
• Approximately 79 million people in 
the US are infected with HPV, and 
approximately 14 million people in 
the US will become newly infected 
with HPV each year.  
• The current number of cancers 
attributable to HPV is rising with 
an estimated 30,700 each year. 
• The 9vHPV vaccine has the potential 
to prevent 92% of the HPV-
attributable cancers.  
• Cervical cancer is the most common 
HPV-associated cancer among women 
and oropharyngeal cancers are the 
most common among men. 
 
We 
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raise 
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cle
s
Ar
nh
ei
m
-D
ah
lst
rö
m
 L
, P
as
te
rn
ak
 B
, S
va
ns
trö
m
 H
, S
pa
ré
n 
P,
 H
vi
id
 
A.
 A
ut
oi
m
m
un
e,
 n
eu
ro
lo
gi
ca
l, 
an
d 
ve
no
us
 th
ro
m
bo
em
bo
lic
 ad
ve
rs
e 
ev
en
ts
 af
te
r i
m
m
un
isa
tio
n 
of
 ad
ol
es
ce
nt
 gi
rls
 w
ith
 q
ua
dr
iv
al
en
t 
hu
m
an
 p
ap
ill
om
av
ir
us
 v
ac
ci
ne
 in
 D
en
m
ar
k 
an
d 
Sw
ed
en
: C
oh
or
t 
st
ud
y.
 B
M
J. 
20
13
 O
ct
;3
47
:f5
90
6.
Ch
ao
 C
, K
le
in
 N
P,
 V
el
ice
r C
M
, S
y 
LS
, S
le
za
k 
JM
, T
ak
ha
r H
, e
t a
l. 
Su
rv
ei
lla
nc
e o
f a
ut
oi
m
m
un
e c
on
di
tio
ns
 fo
llo
w
in
g r
ou
tin
e u
se
 o
f 
qu
ad
riv
al
en
t h
um
an
 p
ap
ill
om
av
ir
us
 v
ac
ci
ne
. J
 In
ter
n 
M
ed
. 2
01
2 F
eb
; 
27
1(
2)
:1
93
-2
03
. E
pu
b 
20
11
 N
ov
.
G
ee
 J,
 N
al
ew
ay
 A
, S
hu
i I
, B
ag
gs
 J,
 Y
in
 R
, L
i R
, e
t a
l. 
M
on
ito
rin
g t
he
 
sa
fe
ty
 o
f q
ua
dr
iv
al
en
t h
um
an
 p
ap
ill
om
av
ir
us
 v
ac
ci
ne
: F
in
di
ng
s f
ro
m
 
th
e V
ac
ci
ne
 S
af
et
y 
D
at
al
in
k.
 V
ac
cin
e. 
20
11
 O
ct
; 2
9(
46
):8
27
9-
84
.
G
rim
al
di
-B
en
so
ud
a L
, G
ui
lle
m
ot
 D
, G
od
ea
u 
B,
 B
en
ic
ho
u 
J, 
Le
br
un
-
Fr
en
ay
 C
, P
ap
ei
x 
C,
 et
 al
. A
ut
oi
m
m
un
e d
iso
rd
er
s a
nd
 q
ua
dr
iv
al
en
t 
hu
m
an
 p
ap
ill
om
av
ir
us
 v
ac
ci
na
tio
n 
of
 y
ou
ng
 fe
m
al
e s
ub
je
ct
s. 
J I
nt
er
n 
M
ed
. 2
01
4 A
pr
; 2
75
(4
):3
98
-4
08
. E
pu
b 
20
13
 N
ov
 22
.
K
le
in
 N
P,
 H
an
se
n 
J, 
Ch
ao
 C
, V
el
ice
r C
, E
m
er
y 
M
, S
le
za
k 
J, 
et
 al
. S
af
et
y 
of
 q
ua
dr
iv
al
en
t h
um
an
 p
ap
ill
om
av
ir
us
 v
ac
ci
ne
 ad
m
in
ist
er
ed
 ro
ut
in
el
y 
to
 fe
m
al
es
. A
rc
h 
Pe
di
at
r A
do
les
c M
ed
. 2
01
2 D
ec
; 1
66
(1
2)
:1
14
0-
8.
M
ac
ar
tn
ey
 K
K
, C
hi
u 
C,
 G
eo
rg
ou
sa
ki
s M
, B
ro
th
er
to
n 
JM
. S
af
et
y 
of
 h
um
an
 p
ap
ill
om
av
ir
us
 v
ac
ci
ne
s: 
A
 re
vi
ew
. D
ru
g S
af
. 2
01
3 J
un
; 
36
(6
):3
93
-4
12
.
M
ar
ko
w
itz
 L
E,
 D
un
ne
 E
F,
 S
ar
ai
ya
 M
, C
he
ss
on
 H
W
, C
ur
tis
 C
R
, G
ee
 J,
 
et
 al
. H
um
an
 p
ap
ill
om
av
ir
us
 v
ac
ci
na
tio
n:
 R
ec
om
m
en
da
tio
ns
 o
f t
he
 
Ad
vi
so
ry
 C
om
m
itt
ee
 o
n 
Im
m
un
iz
at
io
n 
Pr
ac
tic
es
 (A
CI
P)
. M
M
W
R 
63
(R
R0
5)
;1
-3
0
M
or
o 
PL
, Z
he
te
ye
va
 Y
, L
ew
is 
P,
 S
hi
 J,
 Y
ue
 X
, M
us
er
u 
O
I, 
et
 al
. S
af
et
y 
of
 
qu
ad
riv
al
en
t h
um
an
 p
ap
ill
om
av
ir
us
 v
ac
ci
ne
 (G
ar
da
sil
®)
 in
 p
re
gn
an
cy
: 
Ad
ve
rs
e e
ve
nt
s a
m
on
g n
on
-m
an
uf
ac
tu
re
r r
ep
or
ts
 in
 th
e V
ac
ci
ne
 
Ad
ve
rs
e E
ve
nt
 R
ep
or
tin
g S
ys
te
m
, 2
00
6-
20
13
. V
ac
cin
e. 
20
15
 Ja
n;
 33
(4
): 
51
9-
22
.
Sc
he
lle
r N
M
, P
as
te
rn
ak
 B
, S
va
ns
trö
m
 H
, H
vi
id
 A
. Q
ua
dr
iv
al
en
t h
um
an
 
pa
pi
llo
m
av
ir
us
 v
ac
ci
ne
 an
d 
th
e r
isk
 o
f v
en
ou
s t
hr
om
bo
em
bo
lis
m
. 
JA
M
A.
 20
14
 Ju
l;3
12
(2
):1
87
-8
.
Sc
he
lle
r N
M
, S
va
ns
trö
m
 H
, P
as
te
rn
ak
 B
, A
rn
he
im
-D
ah
lst
rö
m
 L
, 
Su
nd
str
öm
 K
, K
at
ha
rin
a F
in
k 
K
, e
t a
l. 
Q
ua
dr
iv
al
en
t H
PV
 v
ac
ci
na
tio
n 
an
d 
ris
k 
of
 m
ul
tip
le
 sc
le
ro
sis
 an
d 
ot
he
r d
em
ye
lin
at
in
g d
ise
as
es
 o
f t
he
 
ce
nt
ra
l n
er
vo
us
 sy
ste
m
. J
AM
A.
 20
15
 Ja
n;
 31
3(
1)
:5
4-
61
.
Sl
ad
e B
A,
 L
ei
de
l L
, V
el
lo
zz
i C
, W
oo
 E
J, 
H
ua
 W
, S
ut
he
rla
nd
 A
, 
et
 al
. P
os
tli
ce
ns
ur
e s
af
et
y 
su
rv
ei
lla
nc
e f
or
 q
ua
dr
iv
al
en
t h
um
an
 
pa
pi
llo
m
av
ir
us
 re
co
m
bi
na
nt
 v
ac
ci
ne
. J
AM
A.
 20
09
; 3
02
(7
):7
50
-7
Th
e 
Ce
nt
er
s f
or
 D
ise
as
e 
Co
nt
ro
l a
nd
 P
re
ve
nt
io
n,
 A
m
er
ica
n 
Ac
ad
em
y o
f F
am
ily
 P
hy
sic
ia
ns
, a
nd
 A
m
er
ica
n 
Ac
ad
em
y o
f 
Pe
di
at
ric
s s
tro
ng
ly 
re
co
m
m
en
d 
ch
ild
re
n 
re
ce
ive
 a
ll 
va
cc
in
es
 a
cc
or
di
ng
 to
 th
e 
re
co
m
m
en
de
d 
sc
he
du
le.
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Cl
in
ic
ia
n 
FA
Q
: C
D
C 
Re
co
m
m
en
da
ti
on
s 
fo
r H
PV
 V
ac
ci
ne
 
2-
D
os
e 
Sc
he
du
le
s 
A
ft
er
 th
e 
O
ct
ob
er
 2
01
6 
A
CI
P 
m
ee
ti
ng
, C
D
C 
no
w
 re
co
m
m
en
ds
 th
at
 1
1 
or
 1
2 
ye
ar
 o
ld
s 
re
ce
iv
e 
2 
do
se
s 
of
 H
PV
 v
ac
ci
ne
 in
st
ea
d 
of
 3
.  
Pa
re
nt
s 
m
ay
 h
av
e 
qu
es
ti
on
s 
ab
ou
t t
hi
s 
ch
an
ge
.  
Th
is
 re
so
ur
ce
 h
el
ps
 
ex
pl
ai
n 
th
e 
re
as
on
s 
fo
r c
ha
ng
in
g 
th
e 
H
PV
 v
ac
ci
ne
 re
co
m
m
en
da
ti
on
, a
nd
 p
ro
vi
de
s 
ti
ps
 fo
r t
al
ki
ng
 w
it
h 
th
e 
pa
re
nt
s 
of
 y
ou
r p
at
ie
nt
s 
ab
ou
t t
he
 c
ha
ng
e.
  
W
ha
t h
as
 c
ha
ng
ed
 in
 th
e 
ne
w
 H
PV
 v
ac
ci
ne
 re
co
m
m
en
da
ti
on
s?
 
In
 O
ct
ob
er
 2
01
6,
 C
D
C 
up
da
te
d 
H
PV
 v
ac
ci
na
tio
n 
re
co
m
m
en
da
tio
ns
 re
ga
rd
in
g 
do
si
ng
 s
ch
ed
ul
es
.  
CD
C 
no
w
 
re
co
m
m
en
ds
 2
 d
os
es
 o
f H
PV
 v
ac
ci
ne
 fo
r p
eo
pl
e 
st
ar
tin
g 
th
e 
va
cc
in
at
io
n 
se
rie
s 
be
fo
re
 th
e 
15
th
 b
irt
hd
ay
.  T
hr
ee
 
do
se
s 
of
 H
PV
 v
ac
ci
ne
 a
re
 re
co
m
m
en
de
d 
fo
r p
eo
pl
e 
st
ar
tin
g 
th
e 
va
cc
in
at
io
n 
se
rie
s 
on
 o
r a
ft
er
 th
e 
15
th
 b
irt
hd
ay
 a
nd
 
fo
r p
eo
pl
e 
w
ith
 c
er
ta
in
 im
m
un
oc
om
pr
om
is
in
g 
co
nd
iti
on
s. 
CD
C 
co
nt
in
ue
s 
to
 re
co
m
m
en
d 
ro
ut
in
e 
va
cc
in
at
io
n 
fo
r g
irl
s 
an
d 
bo
ys
 a
t a
ge
 1
1 
or
 1
2 
ye
ar
s. 
 T
he
 v
ac
ci
na
tio
n 
se
rie
s 
ca
n 
be
 s
ta
rt
ed
 a
t a
ge
 9
 y
ea
rs
.  
CD
C 
al
so
 re
co
m
m
en
ds
 v
ac
ci
na
tio
n 
th
ro
ug
h 
ag
e 
26
 y
ea
rs
 fo
r f
em
al
es
 a
nd
 th
ro
ug
h 
ag
e 
21
 y
ea
rs
 fo
r m
al
es
. M
al
es
 a
ge
 2
2–
26
 y
ea
rs
 m
ay
 b
e 
va
cc
in
at
ed
. 
W
ha
t i
s 
th
e 
re
co
m
m
en
de
d 
2-
do
se
 H
PV
 v
ac
ci
na
ti
on
 s
ch
ed
ul
e?
 
Fo
r g
irl
s 
an
d 
bo
ys
 s
ta
rt
in
g 
th
e 
va
cc
in
at
io
n 
se
rie
s 
be
fo
re
 th
e 
15
th
 b
irt
hd
ay
, t
he
 re
co
m
m
en
de
d 
sc
he
du
le
 is
 2
 d
os
es
 o
f 
H
PV
 v
ac
ci
ne
. T
he
 s
ec
on
d 
do
se
 s
ho
ul
d 
be
 g
iv
en
 6
–1
2 
m
on
th
s 
af
te
r t
he
 fi
rs
t d
os
e 
(0
, 6
–1
2 
m
on
th
 s
ch
ed
ul
e)
.  
A
ns
w
er
in
g 
pa
re
nt
s’
 q
ue
st
io
ns
:  
W
e 
no
w
 re
co
m
m
en
d 
2 
do
se
s o
f H
PV
 v
ac
ci
ne
 fo
r y
ou
r s
on
 o
r d
au
gh
te
r, 
in
st
ea
d 
of
 3
, i
f 
yo
ur
 c
hi
ld
 st
ar
ts
 th
e 
se
rie
s b
ef
or
e 
th
ei
r 1
5t
h 
bi
rt
hd
ay
.  I
 st
ill
 re
co
m
m
en
d 
yo
ur
 c
hi
ld
 st
ar
t t
he
 v
ac
ci
na
tio
n 
se
rie
s b
y 
ag
e 
11
 
or
 1
2 
ye
ar
s f
or
 b
es
t p
ro
te
ct
io
n 
ag
ai
ns
t H
PV
.  H
e 
or
 sh
e 
w
ill
 n
ee
d 
a 
se
co
nd
 d
os
e 
6-
12
 m
on
th
s a
ft
er
 th
e 
fir
st
 d
os
e.
  
W
ho
 s
ho
ul
d 
st
ill
 re
ce
iv
e 
a 
3-
do
se
 s
ch
ed
ul
e?
 
CD
C 
co
nt
in
ue
s 
to
 re
co
m
m
en
d 
a 
3-
do
se
 s
ch
ed
ul
e 
fo
r p
er
so
ns
 s
ta
rt
in
g 
th
e 
H
PV
 v
ac
ci
na
tio
n 
se
rie
s 
on
 o
r a
ft
er
 th
e 
15
th
 b
irt
hd
ay
, a
nd
 fo
r p
er
so
ns
 w
ith
 c
er
ta
in
 im
m
un
oc
om
pr
om
is
in
g 
co
nd
iti
on
s. 
 T
he
 s
ec
on
d 
do
se
 s
ho
ul
d 
be
 g
iv
en
 
1–
2 
m
on
th
s 
af
te
r t
he
 fi
rs
t d
os
e,
 a
nd
 th
e 
th
ird
 d
os
e 
sh
ou
ld
 b
e 
gi
ve
n 
6 
m
on
th
s 
af
te
r t
he
 fi
rs
t d
os
e 
(0
, 1
–2
, 6
 m
on
th
 
sc
he
du
le
). 
A
ns
w
er
in
g 
pa
re
nt
s’
 q
ue
st
io
ns
: 
If 
yo
ur
 c
hi
ld
 st
ar
ts
 th
e 
se
rie
s a
ft
er
 h
is
 o
r h
er
 1
5t
h 
bi
rt
hd
ay
 o
r h
as
 c
er
ta
in
 h
ea
lth
 
pr
ob
le
m
s t
ha
t w
ea
ke
n 
hi
s o
r h
er
 im
m
un
e 
sy
st
em
, h
e 
or
 sh
e 
w
ill
 st
ill
 n
ee
d 
th
e 
3-
do
se
 se
rie
s. 
 W
e 
w
ill
 g
iv
e 
th
e 
se
co
nd
 d
os
e 
1–
2 
m
on
th
s a
ft
er
 th
e 
fir
st
, a
nd
 th
e 
la
st
 d
os
e 
6 
m
on
th
s a
ft
er
 th
e 
fir
st
 d
os
e.
  
W
hy
 d
id
 C
D
C 
m
ak
e 
th
e 
re
co
m
m
en
da
ti
on
 c
ha
ng
e 
to
 a
 2
-d
os
e 
sc
he
du
le
? 
O
ve
r t
he
 p
as
t y
ea
r, 
CD
C 
an
d 
th
e 
A
dv
is
or
y 
Co
m
m
itt
ee
 o
n 
Im
m
un
iz
at
io
n 
Pr
ac
tic
es
 (A
CI
P)
 h
av
e 
be
en
 re
vi
ew
in
g 
da
ta
 
on
 2
-d
os
e 
sc
he
du
le
s, 
in
cl
ud
in
g 
re
su
lts
 fr
om
 s
tu
di
es
 o
f H
PV
 v
ac
ci
ne
s 
th
at
 c
om
pa
re
d 
th
e 
an
tib
od
y 
re
sp
on
se
s 
af
te
r 
2 
do
se
s 
an
d 
3 
do
se
s. 
Th
es
e 
st
ud
ie
s 
sh
ow
ed
 th
at
 th
e 
an
tib
od
y 
re
sp
on
se
 a
ft
er
 2
 d
os
es
 g
iv
en
 a
t l
ea
st
 6
 m
on
th
s 
ap
ar
t 
to
 9
–1
4 
ye
ar
-o
ld
s 
w
as
 a
s 
go
od
 o
r b
et
te
r t
ha
n 
th
e 
an
tib
od
y 
re
sp
on
se
 a
ft
er
 3
 d
os
es
 g
iv
en
 to
 o
ld
er
 a
do
le
sc
en
ts
 a
nd
 
yo
un
g 
ad
ul
ts
, t
he
 a
ge
 g
ro
up
 in
 w
hi
ch
 e
ffi
ca
cy
 w
as
 d
em
on
st
ra
te
d 
in
 c
lin
ic
al
 tr
ia
ls
. 
A
ns
w
er
in
g 
pa
re
nt
s’
 q
ue
st
io
ns
: C
D
C 
an
d 
AC
IP
 (a
 g
ro
up
 o
f e
xp
er
ts
 th
at
 m
ak
e 
va
cc
in
e 
re
co
m
m
en
da
tio
ns
) h
av
e 
be
en
 
re
vi
ew
in
g 
da
ta
 o
n 
2-
do
se
 H
PV
 v
ac
ci
na
tio
n 
sc
he
du
le
s f
or
 se
ve
ra
l m
on
th
s. 
 T
he
 e
vi
de
nc
e 
sh
ow
ed
 th
at
 2
 d
os
es
 o
f H
PV
 
va
cc
in
e 
gi
ve
n 
at
 le
as
t 6
 m
on
th
s a
pa
rt
 in
 y
ou
ng
er
 a
do
le
sc
en
ts
 w
er
e 
as
 g
oo
d 
or
 b
et
te
r t
ha
n 
3 
do
se
s. 
Th
es
e 
up
da
te
d 
re
co
m
m
en
da
tio
ns
 a
re
 a
n 
ex
am
pl
e 
of
 u
si
ng
 th
e 
la
te
st
 a
va
ila
bl
e 
ev
id
en
ce
 to
 p
ro
vi
de
 y
ou
r c
hi
ld
 w
ith
 th
e 
be
st
 p
os
si
bl
e 
pr
ot
ec
tio
n 
ag
ai
ns
t s
er
io
us
 d
is
ea
se
s. 
A
ns
w
er
in
g 
pa
re
nt
s’
 q
ue
st
io
ns
: S
in
ce
 y
ou
r c
hi
ld
 re
ce
iv
ed
 h
is
/h
er
 fi
rs
t d
os
e 
of
 th
e 
H
PV
 v
ac
ci
ne
 b
ef
or
e 
he
/s
he
 w
as
 1
5 
ye
ar
s o
ld
, w
e’
ll 
on
ly
 n
ee
d 
to
 g
iv
e 
1 
m
or
e 
do
se
. 
CS
 H
CV
G
15
-P
TT
-1
06
   
11
/3
0/
20
16
 
N
at
io
na
l C
en
te
r f
or
 Im
m
un
iz
at
io
n 
an
d 
Re
sp
ira
to
ry
 D
ise
as
es
 
O
ffi
ce
 o
f t
he
 D
ire
ct
or
 
  
W
hy
 is
 th
e 
2-
do
se
 s
ch
ed
ul
e 
ch
an
ge
 re
co
m
m
en
de
d 
on
ly
 fo
r g
ir
ls
 a
nd
 b
oy
s 
ag
e 
9–
14
 y
ea
rs
? 
A
CI
P 
m
ak
es
 re
co
m
m
en
da
tio
ns
 b
as
ed
 o
n 
th
e 
be
st
 a
va
ila
bl
e 
sc
ie
nt
ifi
c 
ev
id
en
ce
. I
m
m
un
og
en
ic
ity
 s
tu
di
es
 h
av
e 
sh
ow
n 
th
at
 2
 d
os
es
 o
f H
PV
 v
ac
ci
ne
 g
iv
en
 to
 9
–1
4 
ye
ar
-o
ld
s 
at
 le
as
t 6
 m
on
th
s 
ap
ar
t w
er
e 
as
 g
oo
d,
 o
r b
et
te
r, 
th
an
 3
 d
os
es
 
gi
ve
n 
to
 o
ld
er
 a
do
le
sc
en
ts
 a
nd
 y
ou
ng
 a
du
lts
.  
St
ud
ie
s 
ha
ve
 n
ot
 b
ee
n 
do
ne
 to
 s
ho
w
 th
is
 in
 a
do
le
sc
en
ts
 a
ge
 1
5 
ye
ar
s 
or
 o
ld
er
. 
A
ns
w
er
in
g 
pa
re
nt
s’
 q
ue
st
io
ns
: T
he
 d
at
a 
w
e 
cu
rr
en
tly
 h
av
e 
fr
om
 sc
ie
nt
ifi
c 
st
ud
ie
s (
cl
in
ic
al
 tr
ia
ls
) s
ho
w
ed
 th
at
 2
 d
os
es
 
of
 H
PV
 v
ac
ci
ne
 g
iv
en
 a
t l
ea
st
 6
 m
on
th
s a
pa
rt
 w
er
e 
as
 g
oo
d 
or
 b
et
te
r t
ha
n 
3 
do
se
s i
n 
ch
ild
re
n 
9–
14
 y
ea
rs
 o
f a
ge
. O
ld
er
 
ad
ol
es
ce
nt
s h
av
en
’t 
be
en
 st
ud
ie
d 
in
 th
e 
sa
m
e 
w
ay
, s
o 
w
e 
do
n’
t h
av
e 
in
fo
rm
at
io
n 
av
ai
la
bl
e 
fo
r t
ha
t a
ge
 g
ro
up
. F
or
 th
at
 
re
as
on
, t
he
 re
co
m
m
en
da
tio
n 
fo
r n
um
be
r o
f d
os
es
 h
as
 n
ot
 b
ee
n 
ch
an
ge
d 
fo
r o
ld
er
 a
do
le
sc
en
ts
.  
W
ha
t i
s 
th
e 
re
co
m
m
en
da
ti
on
 fo
r p
er
so
ns
 w
it
h 
im
m
un
oc
om
pr
om
is
in
g 
co
nd
it
io
ns
? 
CD
C 
re
co
m
m
en
ds
 3
 d
os
es
 o
f H
PV
 v
ac
ci
ne
 (0
, 1
–2
, 6
 m
on
th
s)
 fo
r i
m
m
un
oc
om
pr
om
is
ed
 p
eo
pl
e 
ag
e 
9 
th
ro
ug
h 
26
 
ye
ar
s. 
Pe
op
le
 w
ho
se
 im
m
un
e 
re
sp
on
se
s 
m
ig
ht
 b
e 
lo
w
er
, f
or
 e
xa
m
pl
e 
du
e 
to
 H
IV
 in
fe
ct
io
n,
 c
an
ce
r, 
au
to
im
m
un
e 
di
se
as
e,
 o
r t
ak
in
g 
im
m
un
os
up
pr
es
sa
nt
 m
ed
ic
at
io
ns
, s
ho
ul
d 
re
ce
iv
e 
3 
do
se
s 
to
 m
ak
e 
su
re
 th
ey
 g
et
 th
e 
m
os
t b
en
ef
it.
 
H
ow
ev
er
, c
hi
ld
re
n 
w
ith
 a
st
hm
a,
 d
ia
be
te
s, 
an
d 
ot
he
r c
on
di
tio
ns
 th
at
 w
ou
ld
 n
ot
 s
up
pr
es
s 
im
m
un
e 
re
sp
on
se
 to
 H
PV
 
va
cc
in
at
io
n 
ca
n 
re
ce
iv
e 
a 
2-
do
se
 s
ch
ed
ul
e.
 
A
ns
w
er
in
g 
pa
re
nt
s’
 q
ue
st
io
ns
: E
ve
n 
th
ou
gh
 C
D
C 
ha
s r
ec
om
m
en
de
d 
ju
st
 2
 d
os
es
 o
f H
PV
 fo
r k
id
s u
nd
er
 1
5 
ye
ar
s, 
w
e’
ll 
ne
ed
 to
 g
iv
e 
yo
ur
 c
hi
ld
 3
 d
os
es
 b
ec
au
se
 h
e/
sh
e 
ha
s a
 h
ea
lth
 p
ro
bl
em
 th
at
 w
ea
ke
ns
 h
is
 o
r h
er
 im
m
un
e 
sy
st
em
. 
If
 a
 H
PV
 v
ac
ci
ne
 s
er
ie
s 
w
as
 s
ta
rt
ed
 w
it
h 
qu
ad
ri
va
le
nt
 H
PV
 v
ac
ci
ne
 o
r b
iv
al
en
t H
PV
 v
ac
ci
ne
 a
nd
 w
ill
 b
e 
co
m
pl
et
ed
 w
it
h 
9-
va
le
nt
 H
PV
 v
ac
ci
ne
, w
ha
t a
re
 th
e 
in
te
rv
al
s 
fo
r t
he
 re
m
ai
ni
ng
 d
os
es
 in
 a
 3
-d
os
e 
or
 2
-d
os
e 
se
ri
es
? 
If 
th
e 
fir
st
 d
os
e 
of
 a
ny
 v
ac
ci
ne
 w
as
 g
iv
en
 b
ef
or
e 
th
e 
15
th
 b
irt
hd
ay
, v
ac
ci
na
tio
n 
sh
ou
ld
 b
e 
co
m
pl
et
ed
 a
cc
or
di
ng
 to
 
a 
2-
do
se
 s
ch
ed
ul
e.
 In
 a
 2
-d
os
e 
se
rie
s, 
th
e 
se
co
nd
 d
os
e 
is
 re
co
m
m
en
de
d 
6–
12
 m
on
th
s 
af
te
r t
he
 fi
rs
t d
os
e 
(0
, 6
–1
2 
m
on
th
 s
ch
ed
ul
e)
. 
If 
th
e 
fir
st
 d
os
e 
of
 a
ny
 v
ac
ci
ne
 w
as
 g
iv
en
 o
n 
or
 a
ft
er
 th
e 
15
th
 b
irt
hd
ay
, v
ac
ci
na
tio
n 
sh
ou
ld
 b
e 
co
m
pl
et
ed
 a
cc
or
di
ng
 to
 
a 
3-
do
se
 s
ch
ed
ul
e.
 In
 a
 3
-d
os
e 
se
rie
s, 
th
e 
se
co
nd
 d
os
e 
is
 re
co
m
m
en
de
d 
1–
2 
m
on
th
s 
af
te
r t
he
 fi
rs
t d
os
e,
 a
nd
 th
e 
th
ird
 
do
se
 is
 re
co
m
m
en
de
d 
6 
m
on
th
s 
af
te
r t
he
 fi
rs
t d
os
e 
(0
, 1
–2
, 6
 m
on
th
 s
ch
ed
ul
e 
If 
a 
va
cc
in
at
io
n 
sc
he
du
le
 is
 in
te
rr
up
te
d,
 v
ac
ci
ne
 d
os
es
 d
o 
no
t n
ee
d 
to
 b
e 
re
pe
at
ed
.  
 
If
 a
 g
ir
l o
r b
oy
 re
ce
iv
ed
 2
 d
os
es
 o
f H
PV
 v
ac
ci
ne
 le
ss
 th
an
 5
 m
on
th
s 
ap
ar
t,
 d
o 
th
ey
 n
ee
d 
a 
th
ir
d 
H
PV
 v
ac
ci
ne
 
do
se
? 
Ye
s. 
In
 a
 2
-d
os
e 
sc
he
du
le
 o
f H
PV
 v
ac
ci
ne
, t
he
 re
co
m
m
en
de
d 
in
te
rv
al
 is
 6
–1
2 
m
on
th
s, 
an
d 
th
e 
m
in
im
um
 in
te
rv
al
 is
 5
 
m
on
th
s 
be
tw
ee
n 
th
e 
fir
st
 a
nd
 s
ec
on
d 
do
se
. I
f t
he
 s
ec
on
d 
do
se
 is
 g
iv
en
 e
ar
lie
r t
ha
n 
5 
m
on
th
s, 
a 
th
ird
 d
os
e 
sh
ou
ld
 b
e 
ad
m
in
is
te
re
d.
 
A
ns
w
er
in
g 
pa
re
nt
s’
 q
ue
st
io
ns
: T
he
 re
co
m
m
en
de
d 
sc
he
du
le
 is
 2
 d
os
es
 g
iv
en
 6
 to
 1
2 
m
on
th
s a
pa
rt
. T
he
 m
in
im
um
 
am
ou
nt
 o
f t
im
e 
be
tw
ee
n 
th
os
e 
do
se
s i
s 5
 m
on
th
s. 
Be
ca
us
e 
yo
ur
 c
hi
ld
 re
ce
iv
ed
 2
 d
os
es
 le
ss
 th
an
 5
 m
on
th
s a
pa
rt
, w
e’
ll 
ne
ed
 
to
 g
iv
e 
yo
ur
 c
hi
ld
 a
 th
ird
 d
os
e.
 
If
 s
om
eo
ne
 is
 a
ge
 1
5 
ye
ar
s 
or
 o
ld
er
 a
nd
 s
ta
rt
ed
 th
e 
va
cc
in
at
io
n 
se
ri
es
 a
t a
ge
 1
1 
bu
t o
nl
y 
re
ce
iv
ed
 1
 d
os
e,
 h
ow
 
m
an
y 
m
or
e 
do
se
s 
do
 th
ey
 n
ee
d?
  
Th
is
 p
er
so
n 
ne
ed
s 
1 
m
or
e 
do
se
 to
 c
om
pl
et
e 
a 
2-
do
se
 s
er
ie
s, 
w
hi
ch
 is
 re
co
m
m
en
de
d 
be
ca
us
e 
th
e 
va
cc
in
at
io
n 
w
as
 
st
ar
te
d 
be
fo
re
 tu
rn
in
g 
15
 y
ea
rs
 o
ld
. I
n 
a 
2-
do
se
 s
er
ie
s, 
th
e 
se
co
nd
 d
os
e 
is
 re
co
m
m
en
de
d 
6–
12
 m
on
th
s 
af
te
r t
he
 fi
rs
t 
do
se
. I
n 
th
is
 c
as
e,
 th
e 
fir
st
 d
os
e 
w
as
 g
iv
en
 s
ev
er
al
 y
ea
rs
 a
go
, s
o 
th
e 
se
co
nd
 d
os
e 
ca
n 
be
 g
iv
en
 ri
gh
t a
w
ay
. 
Is
 th
e 
9-
va
le
nt
 H
PV
 v
ac
ci
ne
 a
pp
ro
ve
d 
by
 F
D
A
 fo
r u
se
 a
s 
a 
2-
do
se
 s
ch
ed
ul
e?
  
Ye
s, 
in
 O
ct
ob
er
 2
01
6,
 F
D
A
 a
pp
ro
ve
d 
a 
2-
do
se
 s
ch
ed
ul
e 
(0
, 6
–1
2 
m
on
th
s)
 o
f 9
-v
al
en
t H
PV
 v
ac
ci
ne
 fo
r u
se
 in
 g
irl
s 
an
d 
bo
ys
 a
ge
 9
–1
4 
ye
ar
s 
in
 th
e 
U
ni
te
d 
St
at
es
. 
W
ha
t H
PV
 v
ac
ci
ne
s 
ar
e 
cu
rr
en
tl
y 
av
ai
la
bl
e 
in
 th
e 
U
ni
te
d 
St
at
es
? 
Th
re
e 
H
PV
 v
ac
ci
ne
s 
ar
e 
lic
en
se
d 
fo
r u
se
 in
 th
e 
U
ni
te
d 
St
at
es
: 9
-v
al
en
t H
PV
 v
ac
ci
ne
, q
ua
dr
iv
al
en
t H
PV
 v
ac
ci
ne
, a
nd
 
bi
va
le
nt
 H
PV
 v
ac
ci
ne
.  
H
ow
ev
er
, a
ft
er
 th
e 
en
d 
of
 2
01
6,
 o
nl
y 
9-
va
le
nt
 H
PV
 v
ac
ci
ne
 w
ill
 b
e 
so
ld
 in
 th
e 
U
ni
te
d 
St
at
es
. 
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